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Abstract: Extracellular fluid depletion and body sodium loss produces physiological and 
behavioral responses to restore body fluid homeostasis, and these responses are 
influenced by sex hormones. Sodium depletion produced by the natriuretic-diuretic, 
furosemide (FURO) stimulates salt intake that increases progressively with multiple 
FURO treatments, a form of behavioral plasticity that is more pronounced in females. 
Hormonal, osmotic, and neural signals regarding perturbations in sodium balance are 
initially processed within neurons and glia of the hindbrain dorsal vagal complex (DVC). 
Thus, plastic changes to glia and synaptic proteins can alter the effectiveness of synapses 
in the DVC to propagate signals to forebrain areas involved in body fluid regulation and 
thereby produce behavioral plasticity such as, progressive increases in salt intake. Our 
objective was to determine estradiol’s effects on brain plasticity associated with the 
detection of peripheral changes during sodium loss. Accordingly, ovariectomized female 
rats with and without hormone replacement were used to test estradiol’s effects on the 1) 
the time course of changes in glia in the hindbrain DVC, 2) the behavioral and 
physiological responses to repeated FURO-induced sodium depletion, and 3) the changes 
in expression of specific synaptic proteins in the hindbrain DVC after multiple FURO-
induced sodium depletions. Adult female rats were ovariectomized, allowed to recover 
for 7 days, and then given estradiol benzoate (EB; 10 μg/0.1 ml oil, sc) or oil vehicle 
(OIL; 0.1 ml, sc) each week for 3 weeks. Rats were given two s.c injections 1-hour apart 
of FURO (5 mg/kg, s.c.) or 0.15 M NaCl (ISO; 1.0 mL/kg). Separate groups of rats were 
used for immunohistochemical analysis of glial fibrillary acidic protein (GFAP) in the 
dorsal vagal complex 2 h and 18-24 h after FURO/ISO, for urinary sodium and volume 
excretion and water and salt intake after weekly FURO/ISO treatments, and for western 
blot analysis of GFAP, β-actin, and the synaptic protein calcium calmodulin kinase II 
(CaMKII). Water and salt intake was increased in furosemide treated rats compared to 
isosaline treated rats independent of number of depletions. Estradiol produced a greater 
increase in salt intake compared to oil-treated rats after first furosemide-induced sodium 
depletion. Repeated furosemide treatment altered the expression of GFAP and CaMKII in 
the DVC. Estradiol may alter expression of GFAP and CaMKII in the DVC. 
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 Females undergo profound physiological changes throughout the reproductive cycle and 
in pregnancy that differentiate them from their male counterparts and are evolutionarily necessary 
to the continuation of their species. It should be no surprise then that differences exist in complex 
regulatory processes governing the physiology between the sexes. Yet, research into sex 
differences has been slow to come about and far too many foundational studies concerning health 
and disease have been based on male-only populations. For instance, examination of hospital 
admissions of patients treated for cardiovascular disease with biologics that alter body fluid 
dynamics, such as diuretics, has revealed that adverse reactions to drugs differs between the sexes 
and this difference may be due to increased pharmacological effects in females (Rodenburg 2012, 
Juul 2011). The complex physiological mechanisms underlying these differences is yet to be 
determined. Therefore, it is vital that scientific research consider sex as a variable in studies 
outside of reproductive physiology, like body fluid regulation, as it may impact the 
cardiovascular and renal health and the treatment of these diseases in females.   
 Body fluid regulation is the maintenance of body water and body sodium involving 
independent and interdependent central and peripheral systems. For this reason, salt impacts life 
more than any other mineral. Despite the debate over the harmful effects of excess salt, too little 
salt or sodium deficiency has detrimental effects on body fluid balance, neural communication, 
and even successful reproduction (Moinier 2008, Morris 2008, Lesham 2009). 
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Body sodium is regulated to ensure the appropriate volume and content of both water and sodium are 
maintained for survival. For example, sodium loss induced by treatment with furosemide (FURO), a 
natriuretic-diuretic, increases salt intake and circulating angiotensin levels (Jalowiec 1974, Fluharty 
1983, Fregly 1983, 1985, Lundy 2003, Moe 1984, Rowland 1999, Sakai 1986, Lind 1984). The 
compensatory behavioral response of ingesting sodium is controlled by the central nervous system in 
order to regulate blood sodium concentrations, fluid volume, and blood pressure. The central nervous 
system receives neural and hormonal input regarding perturbations in sodium balance from the 
periphery, synthesizes those inputs, and responds by altering motor, hormonal, and neural output to 
maintain homeostasis. Areas of the brain involved in this circuit include circumventricular organs, 
specialized areas that have an incomplete blood-brain barrier due to the presence of fenestrated 
capillaries that, together with astrocyte foot processes, control movement of ions and hormones into 
the brain parenchyma. Sensory circumventricular organs capable of detecting changes in plasma 
osmolarity and responding to peripheral hormones like angiotensin II during fluid challenges are in 
the forebrain, the organum vasculosum of the lamina terminals (OVLT) and the subfornical organ 
(SFO) (Antunes 2004, Daniels 2009), and in the hindbrain, dorsal vagal complex, which includes the 
nucleus of the solitary tract (NTS) and area postrema (AP). Together they serve as the sensors and 
integrative sites for stimulating compensatory behavior by relaying peripheral signals to areas of the 
hypothalamus, such as the paraventricular nucleus (PVN) and the supraoptic nucleus (SON). The 
PVN and SON complete the circuit by producing hormonal signals that are then secreted either 
centrally or peripherally to initiate physiological and behavioral responses to fluctuations in body 
fluid balance. However, it has been difficult to identify central areas that specifically mediate 
behavioral responses such as salt intake to sodium loss. Thus, many investigators focus on areas 
involved in the detection of signal associated with salt loss such as that produced by FURO. 
 A particularly interesting aspect of FURO-induced salt intake is that repeated FURO 
treatments elicit progressively greater increases in salt intake (Sakai 1989), which occurs without 
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greater salt loss. Thus, the change in behavior with each experience of sodium loss suggests brain 
plasticity may be involved, an idea supported by the observation that dendritic spines in the nucleus 
accumbens increase in response to repeated sodium depletions. Moreover, rats having experience 
with sodium depletions display increased exploratory rearing compared to rats without a history of 
sodium depletions (Roitman 2002). The change in behavior with repeated episodes of sodium loss 
suggests brain plasticity may be involved in the detection and integration of signals stimulating salt 
intake.  
 Though plasticity is often associated with recovery of function after debilitating injury to the 
central nervous system, long-term alterations to central nervous system function and morphology also 
may alter physiological and behavioral responses to changing life experiences. Importantly, 
accumulating evidence suggests that plastic changes in the central nervous system can be induced by 
sex hormones, and have functional significance. For example, structural changes in dendritic spines 
of adult hippocampal neurons in response to estradiol are thought to underlie changes in synaptic 
efficacy, thereby providing a mechanism for adaptive behaviors associated with learning and memory 
(Gould 1990, Woolley and McEwan 1993).  Increasing salt intake with repeated sodium depletions 
suggests salt intake is an adaptive behavior to preserve sodium balance. Although the studies of the 
central control of sodium regulation have been conducted primarily in males, important sex 
differences in behaviors associated with sodium balance have been observed. Female rats drink less 
water than do males (Richter 1929), a behavioral change proposed to be due to hormones (Santollo 
2015), and the associated fluid retention and physiological changes may be necessary to support 
successful gestation. Even when fluid balance is relatively stable, female rats consume more sodium 
than do male rats and under conditions of sodium need, consume sodium in excess of the amount 
required to restore homeostasis (Wolf 1982). Our laboratory previously reported estrogen-mediated 
effects on water intake during intracellular and extracellular dehydration (Jones 2009). Interestingly, a 
pronounced sex difference in salt preferences also occurs, suggesting that control of sodium ingestion 
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may be influenced by the organizational and activational effects of estrogen (Curtis 2004), with the 
latter potentially underlying long-term plastic changes in the central control of sodium balance.  
  
Statement of the Problem 
  Little is known about the central mechanisms underlying female behavioral responses in 
body sodium regulation. Therefore, could changes in synaptic efficacy via estradiol modification of 
neuronal or non-neuronal cells in the central circuit regulating body sodium regulation underlie the 
behavioral responses to sodium depletion? 
 
Purpose of the Study 
 The purpose of this study was to examine estradiol’s influences on the central control of 
behavioral responses underlying body sodium regulation via plastic changes in areas associated with 
the detection of peripheral changes during sodium loss. The present series of experiments will use 
ovariectomized female rats with and without hormone replacement to examine the time course of 
changes in astrocytes in the hindbrain dorsal vagal complex after a single furosemide-induced sodium 
depletion, assess the behavioral and physiological effects after multiple furosemide-induced sodium 
depletions, and observe changes in the expression of specific synaptic proteins in the hindbrain dorsal 
vagal complex after a single and multiple furosemide-induced sodium depletions. Identifying the 
mechanisms by which estradiol produces physiological and behaviorally significant effects in body 







REVIEW OF THE LITERATURE 
 A study into estradiol’s influence on the central control of behavioral responses 
underlying body fluid regulation covers subjects encompassing broad and deep literature bases. 
The following review includes background information on body fluid regulation, including the 
physiological and behavioral responses to water and sodium loss as well as the neural circuits 
involved. Progress in understanding estrogen’s influence on body fluid regulation is also 
incorporated and brain plasticity is introduced as a possible means for functional changes that 
alter behavior.  
 
Body Fluid Regulation 
Overview 
 Body fluid regulation is the mechanism by which living systems apply neuroendocrine, 
autonomic, renal, and behavioral processes to balance the intake of water and electrolytes with 
the output, so that the intake always equals the output, thus maintaining the stability of the 
internal environment for proper functioning of cells and tissues (Saladin 2003). Stability is 
achieved by maintaining the volume and solute concentrations within that fluid, or osmolarity 
(Saladin 2003). Osmolarity is primarily determined by the concentration of sodium, thus water 
and sodium regulation are closely interconnected. Deviations in osmolarity and volume are 
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detected by central and peripheral sensors (Antunes-Rodriques 2014). The sensors send 
information about water and/or sodium imbalances to the central nervous system (CNS), which in 
turn integrates the stimuli, and activates behavioral and physiological mechanisms to conserve 
and restore water and sodium levels. Once balance is restored, feedback signals inhibit further 
activation, reset the system, and prevent hazardous lack or excess of water or sodium. While this 
homeostasis is vital for survival, changes in the environment that lead to repetitive experiences 
with water or sodium losses can disrupt homeostasis, threaten that survival, and prompt behavior 
that would normally be inhibited, such as the excessive intake of salt. Prolonged salt intake 
behavior has negative effects on fluid regulation that can be maladaptive and even lead to the 
development of pathological diseases, such as hypertension. Therefore, it is important to 
understand the central control of the behavioral responses to the physiological loss of water and 
sodium.  
 
Physiological Responses to Water and Sodium Loss 
 Water and sodium loss were recognized as important determinants in health and disease 
by physicians early in the 19th century who made great strides in understanding fluid’s functional 
role within the body in order to discover a means for treating patients suffering from circulatory 
collapse due to severe dehydration or blood loss. Pioneers in the field laid the theoretical 
foundation of cellular (Gilman 1937) and extracellular fluid compartmentalization and the 
dynamic involvement of neural, vascular, hormonal, and osmotic systems in body fluid regulation 
(for review see Fitzsimons 1979). Scientific advancements led to McCance’s observations that 
when there is sufficient loss of fluid volume, hypovolemia, which shifts water and electrolytes out 
of the extracellular compartment, sodium is also depleted, hyponatremia, and the correction of 
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this imbalance involves both water and salt intake (McCance 1936). While Guyton et al. (1975) 
described that the physiological responses to hypovolemia and hyponatremia were controlled by 
an interplay between cardiovascular, renal, and neural systems, signifying the difficulty in 
separating the effects of hyponatremia from hypovolemia and isolating the stimulatory 
mechanisms. 
 In hypovolemia, cardiovascular, hormonal, and behavioral compensatory mechanisms are 
activated to maintain vascular volume and blood pressure (Fig. 1). A drop in volume and pressure 
is detected by stretch receptors in blood vessels and baroreceptors in the aorta and carotid sinus of 
the heart. Stimulation by these receptors and the sympathetic nervous system travels to the 
hindbrain of the central nervous system and are further propagated to the hypothalamus. The 
hypothalamus initiates the release of vasopressin from the posterior pituitary. Vasopressin is a 
peptide hormone that upon binding to its receptor, in the kidney increases water reabsorption, and 
in the vascular smooth muscle stimulates vasoconstriction in order to preserve circulatory volume 
(Saladin 2010).  
 In tandem with a loss of volume, the osmolarity initially increases stimulating receptors 
in the hypothalamus and kidney sensitive to osmolarity, or osmoreceptors (Verney 1947). 
Activation of osmoreceptors stimulates vasopressin release to also increase water reabsorption. 
Oxytocin, a hormone similar to vasopressin, is released from the posterior pituitary and increases 
sodium excretion. Together, decreased water loss and increased sodium excretion result in 
maintaining both plasma osmolarity and plasma volume. However, if the circulatory volume is 
restored without replenishment of sodium, the net effect is a dilution of osmolarity which 
stimulates compensatory mechanisms to conserve sodium along with water. Equally important to 
the maintenance of circulation is the renin angiotensin aldosterone system, a local hormonal 
system regulating blood pressure and body fluid balance. 
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Figure 1. Fluid balance via regulation of volume and osmolality.   
The Renin Angiotensin Aldosterone System 
 The renin angiotensin aldosterone system (RAAS) is also involved in the homeostatic 
control of blood pressure, tissue perfusion, and extracellular volume. In response to decreased 
blood pressure, volume, or osmolarity, the RAAS is activated. The RAAS signaling cascade 
begins with the production of renin made in the kidneys (Lavoie 2003). Exocytosis of renin 
occurs upon activation by a change in renal perfusion pressure detected by the arteriole 
baroreceptors and stretch sensitive juxtaglomerular cells in the kidney, a change in chloride 
concentration and delivery of sodium chloride to macula densa cells of the distal tubule in the 
kidney, or an activation of β-1 adrenergic receptors in the heart stimulated by the sympathetic 
nervous system [3]. Renin cleaves angiotensinogen secreted by the liver to form angiotensin I. 
Angiotensin converting enzyme (ACE) in the lungs hydrolyzes angiotensin I (Atlas 2007, Hsueh 
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1991) to form angiotensin II (Ang II). Angiotensin II is the active effector of RAAS and binds to 
angiotensin type 1 receptors (AT-1R). Angiotensin type I receptors are G-protein coupled 
receptors with subtypes found in the many cells of organs (AT-1a) and in the central nervous 
system (CNS) (AT-1b) associated with RAAS physiological and behavioral responses (Zhuo 
2013). Binding of angiotensin II to AT-1 receptors leads to activation of multiple signal 
transduction pathways. The effects of these pathways varies but in general leads to 
vasoconstriction in the vasculature, increased blood pressure, and increased cardiac contractility.  
 In addition, angiotensin II and elevated plasma potassium (K+) increases aldosterone 
release from zona glomerulosa cells of the adrenal glands. Aldosterone is a mineralocorticoid 
hormone that stimulates the reabsorption of sodium and excretion of potassium by binding to 
mineralocorticoid receptors in the kidney. By the reabsorption of sodium and potassium, water is 
indirectly conserved, thereby influencing volume and blood pressure. Angiotensin II also acts in 
the CNS to stimulate vasopressin release from the posterior pituitary in the hypothalamus and 
water and salt intake, discussed further below. Lastly, restoration of blood pressure and 
angiotensin II feedback onto the RAAS pathway serves to shut down the system by inhibiting the 
release of renin (Hall 2010). 
  
Behavioral Responses to Water and Sodium Loss 
 While water and sodium conservation in the kidney is effective at maintaining body fluid 
balance in the short term, the only way to ultimately restore fluid levels is by ingesting water and 
sodium. Experiments on cellular dehydration found water deprivation and administration of 
hyperosmolar solutions were sufficient to stimulate water intake. Using these methods to disrupt 
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osmolarity, researchers were able to determine that the water and sodium loss is detected by 
central osmoreceptors and receptors for sodium (Verney 1947, Andersson 1953). The sites for 
these osmoreceptors are in the circumventricular organs, particularly the organum vasculosum of 
the lamina terminalis (OVLT) (Oldfield et al. 1994), the subfornical organ (SFO) (Watanabe 
2005), and the median preoptic nucleus (MnPO) of the hypothalamus. Removal of any areas 
containing osmoreceptors damages their connections to vasopressin and oxytocin releasing cells 
in the PVN and SON, in turn attenuating drinking behavior in response to hypertonic saline 
infusions (Blass 1968, Coburn and Stricker 1978, Miselis, 1981). Even though drinking water can 
adequately restore balance in cellular dehydration (Wolf 1950, 1958), the same is not true in 
extracellular dehydration, where water intake further dilutes the extracellular compartment. In 
this state, homeostasis can only be restored by ingestion of sodium to restore the osmotic balance. 
Hence, the behaviors of both water and salt intake are stimulated under the control of the CNS in 
response to water and sodium loss. Although the mechanisms underlying salt intake behavior 
have yet to be fully explained. 
 Salt intake as a behavior is an enigma. Salt is physiologically needed by the body to 
function adequately and in that sense, it is understandable that animals would be motivated to 
seek salt in times of need. When salt is readily available though, and there is no deficiency to 
drive salt intake, animals continue to do so even to their detriment. In studies where animals were 
depleted of sodium followed by testing with varying concentrations of saline, depleted animals 
accepted saline solutions at concentrations that would normally be avoided. After a recovery, the 
animals’ preference for saline solutions increased (Bare 1949, Smith and Stricker 1969). The shift 
from need to liking salt is the basis for a line of research trying to unravel the intricate 
physiological, behavioral, and psychological mechanisms underlying salt intake (McCaughey 
1998, Morris 2008, Hurley 2015). In these studies sodium balance is disrupted via hypovolemia 
and/or hyponatremia to stimulate salt intake. 
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 Concomitant with the loss of volume is the loss of sodium, together these stimuli activate 
the RAAS to produce aldosterone and ANGII. Aldosterone and ANGII act in the CNS to 
stimulate drinking and are used in the study of ingestive behaviors. Interestingly, antagonism of 
either central mineralocorticoid receptors (MRs) or angiotensin II receptors alone does not inhibit 
salt intake, but the combination of blocking MRs and administration of captopril, an ACE 
inhibitor, fully attenuates salt intake (Moe et al. 1984, Sakai & Epstein 1986, Fitts and Thunhorst 
1996), demonstrating salt intake involves the cooperation/interaction between the aldosterone and 
angiotensin pathways. Consequently, resulting in the finding of a temporal disassociation 
between the stimulus to drink and the onset of drinking behavior. animals maintained on a sodium 
deficient diet show elevated aldosterone and ANGII (Menachery 1991) but will not consume 
solutions of saline until several days later. The delay in intake is not because of an inability to 
taste the saline (Curtis 2001) but may be due to an inhibitory drive. 
 Another stimuli for thirst during extracellular dehydration is hypovolemic activation of 
baroreceptors terminating in the NTS (Kaufman 1984, Zimmerman 1981). The NTS sends 
projections to the ventrolateral medulla and the lateral parabrachial nucleus, which in turn 
synapse with the SON and PVN, stimulating vasopressin and oxytocin release (Blessing et al. 
1982, Cunningham, Jr. and Sawchenko 1988, Saper 1995, Saper and Loewy 1980). When plasma 
volume is normal, the NTS acts to inhibit the activity of this circuit, although the mechanisms of 
this inhibition are not fully understood. Although, the inhibitory actions of serotonin neurons in 
the dorsal raphe nucleus projecting on the SFO is involved in satiety during sodium ingestion 
following sodium depletion (Franchini 2002, Mecawi 2015).   
 Thus, many investigators focus on areas involved in the detection of signal associated 
with salt loss such as that produced by furosemide. A particularly interesting aspect of 
furosemide-induced salt intake is that repeated furosemide treatments elicit progressively greater 
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increases in salt intake (Sakai 1989), which occurs without greater salt loss. Thus, the change in 
behavior with each experience of sodium loss suggests brain plasticity may be involved, an idea 
supported by the observation that dendritic spines in the nucleus accumbens increase in response 
to repeated sodium depletions. Moreover, rats having experience with sodium depletions display 
increased exploratory rearing compared to rats without a history of sodium depletions (Roitman 
2002). The change in behavior with repeated episodes of sodium loss suggest brain plasticity may 
be involved in the detection and integration of signal stimulating salt intake. 
 
Methods of Producing Water and Sodium Loss 
 The study of body fluid regulation has benefited from techniques which allowed 
researchers to rapidly produce water and sodium loss. While chronically depriving animals of 
water and/or sodium (Swanson, Timson, & Frazier 1935) leads to an eventual state of depletion, it 
also has the negative consequences of generating stress and metabolic consequences that make 
deducing responses specific to fluid challenges difficult. Development of new techniques allowed 
for the determination of the contribution of key molecules, stimuli, and the organ systems 
involved in the physiological and behavioral responses to extracellular dehydration.  
 Early studies disrupted the osmotic balance by producing diuresis with the administration 
of sucrose (Holmes & Cizek 1951) that dropped the extracellular volume, resulting in water 
intake. Interestingly, water intake by the animals remained elevated until they were given salt 
suggesting sodium was necessary for the redistribution of fluid between compartments. In order 
to determine whether the water intake was being stimulated by the loss of volume or by the loss 
of sodium and whether the salt intake was stimulated by sodium depletion or secondarily from the 
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water intake, researchers employed the technique of peritoneal dialysis (Cizek 1951), which 
draws fluid out of circulation and exchanges osmolytes, thus disrupting osmolarity leading to 
volume depletion. By sequentially removing sodium from the diet, the relative responses to 
volume depletion or sodium depletion could be investigated. In experiments where rats were 
dialyzed with glucose then given a two bottle test consisting of one bottle of water and one bottle 
of 3% saline, dialyzed a second time, and then re-tested, rats showed an increased preference for 
saline but not water (Falk 1965). Still, this form of dialysis did not allow for the distinction 
between effects due to hypovolemia and hyponatremia.    
 Dialysis with a hyperoncotic colloid, either peritoneal (Fitzsimons 1961) or subcutaneous 
(Stricker 1966), is a rapid method of isotonic fluid depletion by creating an accumulation of fluid 
at the site of injection that is of the same osmolarity as that in circulation. Rats treated in this 
manner and subsequently given a two-bottle test of water and 1.8 % saline drank more water than 
saline initially, but when re-tested days later, drank greater amounts of saline (Fitzsimons 1971) 
(Stricker & Jalowiec 1970). Therefore, hypovolemia stimulated immediate water intake, but that 
intake could not compensate for the depletion because water alone served to further dilute body 
fluids. Only when osmolarity was reestablished by the ingestion of saline was fluid balance 
restored. Thus, salt intake was shown to be an independent behavior from water intake.  
 Pharmacological agents that activate the RAAS or disturb body fluid balance are often 
used to study the physiological and behavioral regulation of body fluids. For instance, β–
adrenergic substances that lower blood pressure, such as isoproterenol, are used to study the 
mechanisms by which the components of the RAAS contribute to water intake. Alternatively, 
diuretics increase urinary excretion leading to extracellular dehydration. However, it has been 
difficult to identify central areas that specifically mediate behavioral responses such as 
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salt intake to sodium loss. Thus, many investigators focus on areas involved in the 
detection of signal associated with salt loss such as that produced by furosemide. 
Furosemide increases urine flow and urinary sodium loss within an hour after treatment, 
but an 18-24 hour delay typically transpires before rats consume sodium solutions. A 
particularly interesting aspect of furosemide-induced salt intake is that repeated 
furosemide treatments elicit progressively greater increases in salt intake (Sakai 1989), 
which occurs without greater salt loss. Understanding the shift in behavior towards salt intake 
not governed by need, requires studying the changes to the central control of the behavioral 
responses to water and sodium loss. 
Neural Circuits Involved in Water and Sodium Loss   
 Perturbations in water and sodium balance are regulated by the central nervous system, 
which receives neural and hormonal input from the periphery, synthesizes those inputs, and 
responds by altering motor, hormonal, and neural output to maintain homeostasis. A key 
component in these processes is a set of privileged sensory organs, circumventricular organs 
(CVOs), within the brain. These specialized CNS organs have an incomplete blood-brain barrier, 
due to the presence of fenestrated capillaries that, together with astrocyte foot processes, control 
movement of ions and hormones into the brain parenchyma. Their location adjacent to the 
ventricles containing cerebrospinal fluid positions them to allow circulating hormones and 
peptides to access the CNS and for hypothalamic hormones to enter circulation without disrupting 
the blood brain barrier. 
 The dorsal vagal complex (DVC) in the hindbrain includes two sensory circumventricular 
organs, the nucleus of the solitary tract (NTS) and area postrema (AP), that share reciprocal 
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connections and make the DVC an important site for regulatory modulation. The AP is an easily 
accessed, highly vascularized nucleus on top of the medulla in the fourth ventricle just above the 
NTS. Structurally, the AP is made of small neurons, unmyelinated nerve fibers, and glia that 
receive blood through terminal arteries while capillary beds surround the spaces. Administration 
of fluorescently tagged proteins of varying sizes revealed diffusion was dependent on the size of 
the molecule, demonstrating the existences of a gradient within the extracellular spaces with 
larger molecules restricted within the AP and smaller molecules allowed passage (Willis 2007). 
The first studies into the function of the AP found a wide variety of chemicals and toxins 
introduced into the AP would cause nausea in the subjects, which led to it being labeled as a 
“chemical sensor” (Kelly 1982, Ossenkopp 1983, Borison 1989, Leslie and Reynolds 1991). AP 
lesion studies found an attenuation in feeding and drinking behaviors (Contreras et al. 1984) and 
after recovery, preferences for sodium and palatable foods appeared, suggesting the AP was 
involved in the inhibition of salt intake (Miselis et al. 1984, Edwards and Ritter 1981, Contreras 
and Stetson, 1981, Curtis et al. 1999, Edwards et al. 1993, Hyde and Miselis 1984, Wang and 
Edwards 1997, Watson 1985). Increased salt intake was also observed following infusion of 
angiotensin II (Watson 1986). Since then, the features attributed to the AP has grown to include 
the scope of autonomic systems, from cardiovascular, feeding and metabolism to body fluid 
regulation (Leslie, 1986, Borison 1989, Goehler et al. 2006). Modulating the physiological 
regulation of so many pathways is made possible by the absence of a complete blood brain barrier 
and the presence of countless receptors for detecting circulating hormones, such as angiotensin II 
and vasopressin. In essence, the AP becomes active, represented by c-fos neural activation or 
electrical activation, upon intrusion of an above threshold level of many molecules, including 
sodium (Clemente et al. 1957, Borison et al. 1975, Andreoli et al. 1980, Adachi and Kobashi 
1985). Even peripheral infusions of sodium increase c-fos in the AP, whereas sodium depletion 
initiates no response (Miller and Loewy 2014, Miller et al. 2013). Research into the mechanisms 
of detecting sodium status revealed serotonergic neurons in the AP become activated after 
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hypertonic saline infusions (Miller and Loewy 2014) and this activation may involve epithelial 
sodium channels (Miller and Loewy 2014). However, it has been difficult to identify central areas 
that specifically mediate behavioral responses such as salt intake to sodium loss. Thus, many 
investigators focus on areas involved in the detection of signal associated with salt loss. 
 The NTS mediates changes in autonomic nerve activity and sensory detection of 
homeostatic pathways (Miselis 1984). The sensory neurons of the NTS are subdivided according 
to the function of the input it receives, with the rostral level associated with taste processing 
coming from the facial, glossopharyngeal, and vagus nerves, while the caudal level incorporates 
cardio-respiratory and gastrointestinal input. Projections from the NTS go to many areas in the 
brain including the paraventricular nucleus (PVN) in the hypothalamus, the amygdala, and within 
the brainstem, the AP, the parabrachial nucleus, locus coeruleus, and dorsal raphe nucleus 
(Andresen 1994, King 2007). A population of neurons in the NTS relevant to the control of 
sodium balance are the 11-β-hydroxysteroid-dehydrogenase 2 (HSD2) neurons, which have 
mineralocorticoid receptors (MR) for aldosterone (Geerling & Loewy 2006). During sodium 
depletion, aldosterone increases to reduce sodium excretion in the kidney, but its mechanism of 
action in the brain is less understood. Activation of MRs in the NTS increases blood pressure 
(Gomez-Sanchez 1986, Gomez-Sanchez et al. 1990), injection of the MR agonist, 
deoxycorticosterone acetate (DOCA) increases salt intake (Rice and Richter 1943), and 
aldosterone injections into the NTS induce a rapid salt intake (Formenti et al. 2012, Koneru et al. 
2013).  However, a recent study by Wang et al. 2016 showed that when spironolactone, an MR 
antagonist, was injected it failed to abolish the salt intake whereas administration of a G-protein 
coupled estrogen receptor (GPER) antagonist inhibited salt intake. Collectively, the results 
demonstrate that the HSD2 neurons in the NTS are important in the behavioral response to 
sodium loss, but the pathway of action is not yet clear.  
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 Sensory circumventricular organs (Fig. 1) in the forebrain capable of detecting changes in 
plasma osmolarity and responding to peripheral hormones like angiotensin II during fluid 
challenges are the organum vasculosum of the lamina terminals (OVLT) and the subfornical 
organ (SFO) (Antunes 2004, Daniels 2009). Together they serve as the initial sensors and 
integrative sites for stimulating compensatory behavior by relaying peripheral signals to areas of 
the hypothalamus, such as the paraventricular nucleus (PVN) and the supraoptic nucleus (SON). 
The PVN and SON complete the circuit by producing hormonal signals that are then secreted 
either centrally or peripherally to initiate physiological and behavioral responses to fluctuations in 
body fluid balance. Direct stimulation of the SFO with ANGII increases drinking and intravenous 
administration of ANGII increases c-fos, a marker of neural activation (McKinley 1992). Too, 
vasopressin and oxytocin secretion increases with the stimulation of the SFO (Ferguson & 
Kasting 1986, 1987, 1988, Holmes et al. 1987, Simpson 1981). Together, this established the 
SFO as an important relay center for regulation of integrated autonomic function.  
 
Figure 2. Sensory circumventricular organs and AngII-sensitive sites in the brain. Sensory 
CVO structures are shown in red and the location of several prominent AngII-sensitive sites are 
shown in blue. Reproduced with permission from Elsevier June 7, 2018; Daniels, D., and S. J. 





 Brain plasticity refers to physical changes in the structure of the brain that can alter its 
function. It includes changes to neurons or non-neuronal cells, like glia, that alter 
neurotransmission. Often brain plasticity is correlated with behavioral changes related to 
experience and can be affected by numerous factors such as, stress, age, and hormones. 
 
Synaptic Efficacy 
 Neural communication relies on the conversion of the electrical signal of an action 
potential to a chemical signal of neurotransmitter release or excitation-secretion coupling (Stahl 
2013) across the synaptic cleft. Neurotransmitter is actively pumped into small endosomal 
packages called synaptic vesicles. Synaptic vesicles are stored in pools near active zones of the 
presynaptic terminal, where they are held in place by actin and synapsin I proteins until 
exocytosis (Sudhof 2004). Mitochondria provide the energy for synthesis of neurotransmitters, 
vesicle formation and trafficking. Sodium entering the axon terminal, or synaptic bouton, by 
opening of voltage sensitive sodium channels as the action potential propagates down the axon, 
activates voltage sensitive calcium (Ca2+) channels (Stahl 2013). Calcium enters and binds to 
calmodulin. Ca2+/calmodulin then binds to Ca2+/calmodulin-dependent protein kinase II (CaM 
kinase II) activating the kinase to phosphorylate synapsin I, in turn releasing the synaptic 
vesicle(Sudhof 2004, DeLorenzo 1981). Synaptic vesicles are coated in a large targeting protein 
complex of Rab GTPase proteins, soluble N-ethylmaleimide-sensitive factor attachment receptors 
(v-SNARE), and filament proteins which will traffic the vesicle to the plasma membrane using 
the cytoskeleton (Gundelfinger 2003, Haucke 2011, Bajjalieh 1999). The vesicular proteins, 
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synapsins, synaptobrevins, and synaptophysins also serve to recognize the presynaptic membrane, 
and aide in trafficking, fusion, and pore formation through interactions with presynaptic 
membrane proteins, syntaxin, physophilin, and t-SNARE (Sudhof 2004). Neurotransmitter 
exocytosis occurs when an increase in Ca2+ at the membrane is detected by calcium-dependent 
activator protein for secretion (CAPS) and fusion is completed by synaptotagmin interacting with 
SNARE proteins (Bajjalieh 1999). Empty vesicles are either recycled or re-filled and re-used 
(Sudhof 2004), and once a neurotransmitter is released from the presynaptic terminal, it is 
degraded or removed from the synaptic cleft. Therefore, successful neurotransmission involves 
coordinated responses of many proteins and modulation of these proteins in turn can effect 
neurotransmission.  
 
Role of Glia in Synaptic Efficacy 
 Though glia are best known for their contributions supporting the blood brain barrier, glia 
functions now include maintaining the synapse and promoting synaptic transmission. Early 
studies in frogs and mud puppies found a correlation between neuronal activity and changes in 
glia, when glial cells with no connection to neurons were depolarized after the associated optic 
nerve was stimulated (Orkand 1966). The depolarization was caused by K+ released from neurons 
that had been taken up by the astrocytes (Walz 2000), pointing to a potential means by which glia 
can alter synaptic transmission by controlling ion concentrations in the extracellular space. Glial 
gap junctions, the intercellular connections between cells, have been found to facilitate the 
removal of ions, neurotransmitters, and metabolites from synapses (Barres 2008), and mediate the 
communication between the neuron and astrocyte (Froes 1999). Signaling between astrocytes in 
the form of calcium (Ca2+) waves propagates via diffusion of inositol-1,4,5-triphosphate 
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(Ins(1,4,5)P3) (Sneyd 1995) and adenosine triphosphate (ATP) (James 2001) through gap 
junctions, and neuronal presence may up-regulate gap junction proteins in glia (Rouach 2000), 
providing a means for glia-neuronal communication.  
 The close association of neuroglia to neurotransmitter release sites (presynaptic 
membrane and postsynaptic membrane) form the tripartite synapse (Arauque 1999), and the 
presence of receptors for common neurotransmitters on neuroglia make them ideal to receive 
chemical information from neurons. Integration and modulation of neuronal activity can be seen 
when synaptic release of neurotransmitters such as glutamate (Porter 1996), acetylcholine, 
norepinephrine, and gamma-aminobutyric acid (GABA) (See review Hayden 2001) produces 
increased Ca2+ in glia (Cornell 1990). Changing Ca2+ levels is thought to ‘activate’ glial cells 
(Hansson 2003). Glial responses include propagating signals which may lead to long-term 
potentiation (Allen 2005), converting neurotransmitters like glutamate into glutamine or 
molecules that can then be re-used by neurons (Auld 2003), and activating release of astrocytic 
transmitters (gliotransmitters) to modulate synaptic transmission by activating receptors on 
neurons (Fiacco 2004, Liu 2004).  
Astrocytes 
 Astroglia or astrocytes are a subset of glia that associate with every part of neurons, 
enveloping synapses and covering blood vessels, where they bring nutrients to neurons, aid in 
maintaining homeostasis by regulating ions and metabolites, serve as a barrier, and guide neural 
development (Hansson 2003, Hatten 1990). Astrocytes extend or retract their processes through 
the interactions with actin allowing them to change from a flattened shape to a stellate or star 
shape (Hatten 2002). Astrocytes express transporters and receptors enabling them to bind 
neurotransmitters or molecules, effecting diffusion and volume of the extracellular space (Hatten 
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2002, Sykova 2000). They can also have activational or modulatory roles in neurons through the 
release of gliotransmitters, including ATP and D-serine. ATP released from astrocyte lysosomes 
can be converted to adenosine, which then binds to presynaptic receptors on neurons to inhibit 
Ca2+ channels, thereby reducing synaptic vesicle release of neurotransmitters (Zhang 2003). 
Astrocytic release of D-serine acts as an agonist for glycine binding sites on postsynaptic N-
methyl-D-aspartate (NMDA) receptors (Mustafa 2004), thereby opening ion channels and 
activating calcium-dependent signaling cascades. Studies have also shown astrocytes release 
glutamate in neuron free cultures (Jeftinija 1996) and by inferring that glutamate detection near 
neuron-glia synapses (Bezzi 1998) or on oligodendrocyte precursor cells (Paukert 2006) after glia 
activation demonstrates astrocytic glutamate release. However transcriptome analysis has 
revealed astrocytes do not express any known vesicular glutamate transporters (Barres 2008). 
Therefore, further studies are needed to determine glutamate release by glia, the mechanism of 
release, and whether its function is to feedback onto neurons to regulate synaptic transmission. In 




 Estradiol is the predominant estrogen and is one of many fat-soluble steroid hormones 
derived from cholesterol that pass easily through cell membranes and participate in biochemical 
reactions (Nelson 2011) influencing the control of many physiological and behavioral processes. 
Estrogen’s actions on reproductive physiology have been well studied and include the 
development of female secondary sexual characteristics, the initiation of changes in the female 
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corpus luteum, uteri, and genital tract (Nelson 2011), and the regulation of sodium transporters in 
the ducts of the epididymis of male testis effecting sperm concentration (Hess 2003). 
Reproductive physiology and mating behavior research led to the discovery of the sex hormones, 
testosterone (Brown-Sequard 1889) and estrogen (Diabetes 2005) and formulating the 
organizational-activational hypothesis to test differences observed between the sexes in 
physiology and behavior. Early studies such as these, broadened sex differences research to 
include studies in non-reproductive systems such as, the brain circuits (Remage-Healey 2014) 
involved in learning and memory (McEwen 1999), energy metabolism, neuroprotection (Arevalo 
2015), and body fluid regulation (Curtis 2009). Studying estrogen influences on the central 
control of body fluid regulation will improve our understanding of how estrogen produces 
physiologically and behaviorally significant effects that may impact women’s health.   
 
Estrogen Mechanisms of Action 
 When studying estrogen effects on sex differences in physiology and behavior, 
consideration must be given to estrogen’s organizational and activational effects. During 
embryological, fetal, and perhaps pre-pubertal development, estrogen’s organizational effects act 
to permanently organize tissues so they differentially function upon gonadal hormone exposure 
later in life. For example, due to organizing effects of estrogen during development, estrogen is 
thought to protect female offspring from the effects of maternal hypertension during pregnancy 
and confer resistance to the development of early-onset hypertension in adulthood, whereas male 
offspring acquire no protection (Xue 2014, 2017). The activational effects are cyclical, acute, and 
reversible (Arnold 2009), as in the well observed effects during the female menstrual cycle when 
estrogen levels rise and fall over a relatively short time. Technological advances enabled 
scientists to study the cellular and molecular mechanisms that underlie the differences between 
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the actions of organizational and activational estrogen effects and demonstrate hormones act 
through many target tissues in separate and distinct processes (McCarthy 2008).  
 Estrogen effects produced over time with exposure involve estrogen acting on processes 
to change gene expression, whereas other effects are too rapid to be explained by genomic 
processes and utilize non-genomic methods to influence cell signaling. Estrogen exerts its 
genomic action by binding to its receptors (ERs), which are ligand-activated transcription factors. 
When estrogen binds to its receptor, the receptor trans-locates to the nucleus, changes its 
conformation, and complexes with coactivator proteins. The estrogen receptor complex then 
binds with an estrogen response element (ERE) in the promoter region of genes to modify 
transcription. Such direct modification is considered the classic method by which estrogen uses 
the nuclear receptors, ER-α or ER-β, to alter gene expression. Alternatively, estrogen can interact 
with other transcription factors, altering their expression or function to indirectly influence gene 
transcription. Regulating transcription is one of the ways estrogen acts to alter proteins, like 
receptors, and thus alter physiology. In reproduction, uterine contractions are stimulated when 
oxytocin binds to its receptor. Estrogen influences this process by increasing the expression of the 
oxytocin receptor (Heldring 2007).  
 Recently, rapid effects of estrogen have been recognized that cannot be explained by 
estrogen’s genomic mechanisms. The findings that estrogen’s non-genomic actions can modulate 
cell signaling (McEwen 2001, Gillies 2010) led to the discovery of the membrane estrogen 
receptor (mER) and the G-protein coupled receptor (GPER). Activation of membrane receptors 
revealed estrogen can alter intracellular second messengers, signal-transduction cascades, ion 
fluxes (calcium), cyclic AMP, and protein kinase pathways. Review of rapid estrogen signaling in 
the brain (see Raz 2008) Rapid effects of estrogen are seen when mice are tested for learning and 
brain plasticity and these effects are due to increase dendritic spine density and GPER 




Estrogen Effects on the Control of Body Fluid Regulation 
 Differences in the regulation of volume and osmolarity have been observed in pregnancy, 
across the reproductive cycle, and in hormone replacement therapy. Pregnant and lactating rats 
increase saline intake and maintain that increase throughout pregnancy (Richter 1938). Denton et 
al. observed increased salt intake in pregnant and lactating rabbits (Denton et al. 1971) and when 
estradiol or progesterone was administered to rabbits, salt intake only increased in rabbits given 
estradiol. Depriving lactating rats of sodium also produces increased sodium intake (Thiels 1990). 
Hence, the differences in salt intake were attributed to changes in the estrogen (Denton et al. 
1971, 1973). Increases in thirst have also been observed in females prior to menstruation (Holmes 
1967, Tarttelin & Gorski 1971) thought to be associated with premenstrual fluid retention and the 
variation in plasma volume across the estrous cycle (Slimmer 1996). 
 In general, female rats drink more saline (Krecek 1972, Richter 1929, Curtis 2004, 
Santollo 2015) than do males even when fluid balance is relatively stable. When body fluid 
balance is disrupted by osmotic challenges, estradiol has effects on water and salt intake (Curtis 
2015). After hypertonic saline infusion, estradiol- treated rats respond by rapidly ingesting water 
(Jones 2009) and after sodium depletion, rats consume sodium in excess of the amount required 
to return to a balanced state (Wolf 1982, Sakai 1989). Such differences are due to the cyclic 
changes in the ovarian hormone, estrogen, and salt intake behavior shows sex differences, in part, 
due to differences in body weight (Santollo 2017). Estrogen is aromatized from androgen 
precursors by the enzyme aromatase in the brain (Roselli 1997) and reproductive organs of both 
males (Hess 1997) and females. Therefore, studying sex differences in target tissues and actions 




 Behavioral changes in fluid intake by estrogen are mediated via interactions with 
estrogen receptors (ERα, ERβ, GPER) in key areas of the brain, including the hypothalamus 
(Santollo 2015). ER expression can be altered by osmotic stimuli, in turn impacting the effect of 
steroid hormones (Somponpun 2003). For example, the vasopressin (AVP) system shows sex 
differences via actions through ERs (Sladek 2008, Lucio-Oliveira 2015), as male rats have greater 
resting plasma AVP levels, greater AVP sensitivity and denser AVP projections (Carter 2009) 
and in females estradiol benzoate (EB) treatment lowers the osmotic threshold of AVP 
(Stachenfeld 2008). The consequences of these sex differences are females display increased salt 
intake and less AVP sensitivity to that intake while males display limited salt intake and are more 
sensitive to AVP.  
 Physiological differences in the control of circulation can also be seen in young women, 
who generally have lower blood pressure than young men (Joyner 2015) and after ovariectomy, 
when ovarian hormones are decreased and resting blood pressure increases. The changes are 
attributed to estradiol modulation of the autonomic nervous system, specifically in volume 
regulation by aldosterone and responses to ANG II (Toering 2017). Hence, sex differences in 
blood pressure and cardiovascular disease have been interpreted to arise from sex differences in 
the renin angiotensin aldosterone system (RAAS). Studies investigating estrogen’s effects on the 
RAAS to mediate cardio-protective effects have produced conflicting results and continues to be 
masked in controversy. Estrogen’s effects vary across the menstrual cycle, method of hormone 
replacement, or in the tissue being studied (Daniels 2009, Stachenfeld 2008). In general, estrogen 
has been found to increase the vasodilatory components of the RAAS, angiotensinogen, AT-2, 
Ang-(1-7), and ACE2, while decreasing the vasoconstrictive hypertensive components, renin, 
aldosterone, and ACE (Daniels 2009, Stachenfeld 2008, Komukai 2010).  
 In addition, estradiol acts on areas of the brain involved in the regulation of sympathetic 
outflow and blood pressure (Hay 2014). Baroreflex function is altered in females after estradiol 
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treatment, as demonstrated by the increases baroreflex sensitivity by modulation of ERα in the 
NTS (Spary 2010) and the correlated decrease in oxytocin in the PVN (DeMelo 2016), mediated 
by a decrease in ERβ expression (Somponpun 2004). Also in the hindbrain, neural activation 
decreases in areas involved in body fluid regulation by estradiol-treated rats (Jones 2012). 
Moreover, central infusions of ANG II induce water intake that may be regulated by estrogen 
treatment (Jonklaas 1984) mediated by increasing neural activation in PVN vasopressin neurons 
(Kisley 2000) and blocked with antiestrogen (Kisley 1999). Similarly, in reaction to ANG II or 
hypernatremia, estrogen changes the response of neurons in the SFO that project to the SON 
(Ciriello 2013). In regards to body sodium regulation, serotonin neurons increase after sodium 
depletion in rats treated with estradiol and has been linked to the inhibition of salt intake 
(Dalmasso 2011). Nonetheless, this cannot explain how estrogen influences the removal of this 
inhibition to allow salt intake, nor does it provide a mechanism for the enhanced salt intake 
observed in females. Investigations into estrogen modifications of salt intake behavior may 
benefit from studies comparing the expression of genes or proteins involved in the synaptic 
plasticity of neural circuits following water and sodium loss. 
 
Estrogen Influences on Synaptic Efficacy  
 Synaptic efficacy centers on the strength of the synapse and relies on the functioning of 
each process of neurotransmission from the presynaptic terminal to the postsynaptic terminal. 
One way estrogen can affect synaptic efficacy is by altering the presynaptic release of 
neurotransmitter. An example of this can be seen when estrogen increases expression of 
vasopressin in areas of the brain influencing social memory (Fink 1996). Estrogen effects have 
also been discovered to impact synaptic efficacy by acting on interneurons where a decrease in 
the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) (Murphy 1998) alters 
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dendritic spine density (Woolley 1992) in hippocampal cells. Too, ER agonist activity shows 
estrogen regulates the expression of synaptic proteins (Waters 2009) and increases the number of 
synaptic boutons (Woolley 1996), thereby increasing synaptic efficacy. In the circuits of learning 
and memory, estrogen modulates synaptotagmins (Crispino 1999) and CAMKII (Sawai 2002). 
Could these proteins also be involved in estrogen mediated enhancement of salt intake behavior? 
 
Estrogen Influences on Glia 
 Organizational estrogen exposure during radial glia formation, differentiation, and 
migration may impact the abundance of glia in distinct areas or preferentially guide 
differentiation to a particular type of glia in certain areas. Estrogen may act to promote the 
process of gliogenesis, or inhibit the processes of cell death, leading to increased numbers of glial 
cells. Developing glia may be uniquely influenced by estrogen, such that the phenotype of glia is 
altered or sensitized to change specific responses to growth hormones, neurotrophic factors, or 
second messengers upon adult exposure to estrogen through the regulation of receptor expression. 
For instance, I recall reading that there are sex differences in dendritic branching and the pruning 
process in adults. The mechanisms by which astrocytes are activated and participate in these 
processes may be modified during development by estrogen. Too, with the newly recognized 
implications of epigenetics, its possible effects of estrogen on transcription may be 
organizationally altered due to estrogen modulation of epigenetic mechanisms on chromatin to 
silence genes.   
 Activational responses to estrogen occur upon re-exposure and may include estrogen 
upregulation of estrogen receptors in glia to regulate glial functions, where estrogen binds to 
estrogen receptors on glia to produce changes in Ca2+ signaling (Kuo 2010). Additionally, 
estrogen may also regulate the production of gliotransmitters either directly via estrogen receptor 
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mediated modulation of transcription or indirectly by regulating the production of the rate 
limiting enzymes for the transmitters. In this way estrogen can act through estrogen response 
elements at the promoter region of genes specific for glial receptors to induce activational 
regulation of glial neuronal communication. In response to brain injury, estrogen has been found 
to have protective effects, even participating in the repair process itself. Local production of 
estrogen by aromatase synthesis in astroglia is believed to aid in neural repair (Saldanha 2009). 
Studies investigating the effects of estradiol treatment on the development of neuro-psychiatric 
disorders found estradiol binding to ERα expressed on astrocytes had beneficial effects in 
experimental autoimmune encephalomyelitis (Spence 2011). Finally, the outcome of estrogen’s 
effects may be a consequence of the summation of both organizational and activational effects. 
Still, little research has looked into the influence of estrodial on glia in response to water and 
sodium loss.  
 
 In summary, the brain is a powerful integrator of sensory information for regulating 
physiological processes with precision and urgency, including body fluid regulation. Yet, 
experiences and exposure to hormones change it in ways we still do not fully understand. Nor 
have we realized the impact brain plasticity may have on behaviors associated with regulated 
physiological processes. Investigating estradiol’s influence on synaptic efficacy after sodium 
depletion will improve our understanding of the brain plasticity underlying the behavioral 






MATERIALS AND METHODS 
Animals 
White albino rats (Rattus norvegicus) of the Sprague-Dawley strain were purchased from Charles 
River or obtained from breeding colonies at Oklahoma State University Center for Health 
Sciences. Adult female rats weighing 220 – 375 g at the beginning of the experiment were 
individually housed in plastic cages in a temperature controlled (21-25°C) room with a 12-hr 
light-dark cycle and given ad libitum access to rodent chow (Harlan #2018) and water. All 
procedures were approved by the Oklahoma State University Center for Health Sciences Animal 
Care and Use Committee in accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. 
Ovariectomy and Hormone Replacement  
Rats were weighed and anesthetized with either sodium pentobarbital (Pbt; 50 mg/kg body weight 
(bw), i.p.) or isoflurane (2-2.5%; 1.5 -2 L/min flow rate). The ventral abdomen was shaved, 
disinfected with Betadine, wiped with alcohol, and treated with topical anesthetic (Bupivicaine; 5 
mg/kg). A single longitudinal incision was made at the midline and the muscle incised to access 
the ovaries. Ovaries were bilaterally removed by first tying off each uterine horn, cauterizing the 
blood vessels, and then excising the ovary distal to the suture. The muscle was closed with 
sutures and the skin closed with stainless steel staples. Rats were given Meloxicam (1.5 mg/kg 
bw, p.o.) for postoperative pain management and allowed to recover. Seven days after 
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surgery, ovariectomized animals were given s.c. injections of the sesame oil vehicle (OIL; 0.1 ml) 
or 17-β-estradiol-3-benzoate (EB; Fisher Scientific; 10 μg/0.1 ml sesame oil) to mimic the pattern 
of estrogen fluctuations in reproductively intact rats (Curtis 2015). Specifically, rats were given 




Figure 3. Timeline of hormone replacement regimen. Seven days after ovariectomy, rats 
received s.c. injections of EB or OIL between 09:00-11:00 on days 1 and 2 of a 4-day regimen. 
Rats were tested or terminated on day 4 as described in the experimental protocols. 
 
Rats were weighed on each of these days and the efficacy of hormone replacement was 
determined by assessing the change in body weight (McCarthy 1991; Geary 1994; Graves 2011; 
Curtis 2015). As an additional verification of hormone efficacy, uterine weight was assessed at 
termination (Cooke 1997; Graves 2011; Miura 1971). Uteri were collected at sacrifice and stored 
in 0.15 M NaCl. Adipose was removed from the uteri, a 10-mm segment of uterus was cut near 
the bifurcation of the uterine horn, and then weighed. 
 
Furosemide Treatment 
Between 09:00-11:00 am on the morning of injections, food and water were removed from cages 
and OIL- and EB- treated rats were randomly assigned to be given two s.c injections of 
furosemide (FURO; 5 mg/kg bw) or 0.15 M NaCl (ISO; 1.0 mL/kg bw) separated by one hour 
(Sakai 1989). Rats were weighed before each injection and, following injection, returned to clean 
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cages. Testing or termination after FURO treatment followed three separate protocols. For one 
group of OIL- and EB-treated rats, rats were given injections of FURO or ISO on day four of the 
hormone regimen as described above. After the second injection, rats were returned to their cages 
for 2 h without access to food or water. Rats in this 2 h FURO protocol (Figure 4) were weighed 
and then either tested or terminated.  
 
Figure 4. Timeline of 2 h FURO treatment protocol. Seven days after ovariectomy on day 4 of 
the hormone regimen, rats were adapted to the testing procedures. One week later, on day 4 of the 
hormone regimen, rats were given two s.c. injections of FURO (FURO; 5 mg/kg bw) or 0.15 M 
NaCl (ISO; 1.0 mL/kg bw) separated by one hour. Two hours after the second injections, rats 
were tested or terminated. 
 
A second group of OIL- and EB-treated rats were given injections of FURO or ISO on day three 
of the hormone regimen as described (Figure 3). After the second injection, rats were returned to 
their cages for 18-24 h, during which they had access to water but not chow. On day four, rats in 
this single 18-24 h FURO protocol (Figure 5) were weighed and then either tested or terminated.  
 
Figure 5. Timeline of 18-24 h FURO treatment protocol. Seven days after ovariectomy on day 
4 of the hormone regimen, rats were adapted to the testing procedures. One week later, on day 3 
of the hormone regimen, rats were given two s.c. injections of FURO (FURO; 5 mg/kg bw) or 
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0.15 M NaCl (ISO; 1.0 mL/kg bw) separated by one hour. 18-24 hours after the second injections, 
rats were tested or terminated. 
 
A third group of OIL- and EB-treated rats were given FURO or ISO treatment on day three of the 
hormone regimen as described (Figure 4). On day four, rats in this multiple 18-24 h FURO 
protocol (Figure 6) were weighed and then tested. Following testing, rats were returned to cages 
and given ad libitum access to both food and water for three days. This procedure was repeated at 
weekly intervals for a second and third week. On day four of the third week, rats were tested or 
terminated. 
Figure 6. Timeline of multiple 18-24 h FURO treatments protocol. Seven days after 
ovariectomy on day 4 of the hormone regimen, rats were adapted to the testing procedures. One 
week later, on day 3 of the hormone regimen, rats were given two s.c. injections of FURO 
(FURO; 5 mg/kg bw) or 0.15 M NaCl (ISO; 1.0 mL/kg bw) separated by one hour. 18-24 hours 
after the second injections, rats were tested.  This procedure was repeated at weekly intervals for 
a second and third week. On day four of the third week, rats were tested or terminated. 
 
Experiment 1: Furosemide Effects on Glia in the Dorsal Vagal Complex 
Experiment 1 compared changes in astrocytes in the hindbrain dorsal vagal complex of separate 
groups of OIL- and EB- treated rats given FURO or ISO treatment using the 2 h protocol (ISO: 
OIL n = 4-6; EB, n = 3-5; FURO: OIL n = 4-7; EB, n = 4-6) or the single 18-24 h protocol (ISO: 
OIL n = 2-3; EB, n = 3-5; FURO: OIL n = 4-5; EB, n = 3) as described (Figures 4 and 5). In this 
experiment, animals were added to increase the power groups of identically treated and processed 
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rats from previous FURO studies in our lab (Curtis 2015; Core 2017), using remaining tissue 
from a 1:3 series (see below for tissue collection). 
Perfusion, Termination, and Tissue Collection 
At sacrifice, rats were weighed and then anesthetized with sodium pentobarbital (Pbt; 50 mg/kg 
bw, i.p.). After rats failed to respond to tail and paw pinches, they were placed on a perfusion tray 
in a fume hood. The lower abdomen was incised and this incision was expanded through the 
diaphragm and ribs to expose the heart. Blood samples were collected from the heart into 
heparinized tubes for analysis of plasma protein, sodium, potassium, and osmolality; aliquots 
were collected into micro-hematocrit capillary tubes for analysis of hematocrit. Rats then were 
perfused transcardially with 0.15 M NaCl followed by 4% paraformaldehyde. Brains were 
removed, post-fixed in 4% paraformaldehyde overnight, and then transferred to a 30% sucrose 
solution, and stored at 4° C. 
Uteri were collected and analyzed as described (Ovariectomy and hormone replacement). Blood 
samples were centrifuged at 5000 rpm for 20 minutes. Following centrifugation, plasma was 
aliquoted into Eppendorf tubes. One to two drops of plasma were analyzed for protein 
concentration using a refractometer (Leica). Remaining plasma was frozen at -80°C for later 
analysis of plasma sodium and potassium concentration using an ion-sensitive electrode system 
(EasyLyte). Plasma osmolality was determined using a Capillary tubes were centrifuged at 12000 
rpm for 5 minutes. The ratio of the volume of red blood cells to the volume of the whole blood 
was calculated and used to determine hematocrit. 
Immunohistochemistry 
Fixed brains were cut in coronal sections at 40 μm in a 1:3 series through the forebrain and 
hindbrain using a cryostat (Leica) and then stored in cryoprotectant (Watson 1986) at -20° C until 
processed for immunolabeling. One of the three series of free-floating brain sections were 
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processed for glial fibrillary acidic protein (GFAP; a marker for astrocytes). Briefly, tissue 
sections were rinsed in 0.05 M Tris-NaCl, incubated in 0.5% H2O2 for 30 min, rinsed again, and 
then incubated in 10% normal goat serum (NGS) in 0.05 M Tris-NaCl with 0.5% Triton-X for 60 
min. Tissue sections then were incubated overnight in primary antibody (Millipore: mouse anti-
GFAP) diluted 1:6,000 in 2% NGS on a rocker at 4° C, then rinsed with 2% NGS and incubated 
in goat anti-mouse IgG (Jackson Immunoresearch; Cy3) diluted 1:200 in 2% NGS for 4-6 hours 
on a rocker at room temperature. After final rinses, sections were mounted on gelatinized slides, 
dried overnight, dehydrated in alcohol and xylenes, and then cover slipped using Cytoseal 60 
(Fisher Scientific). 
Image Analysis and Quantification 
Viscerosensory information is initially integrated in the hindbrain dorsal vagal complex which 
comprises the nuclei of the area postrema, the nucleus of the solitary tracts, and the dorsal motor 
nucleus of the vagus. Because the dorsal vagal complex encompasses regions that can be 
subdivided based on function (Swanson 1980), immunohistochemical analysis was conducted 
within these subdivisions. The area postrema (AP; Bregma -13.68 to -14.08) and nucleus of the 
solitary tract (NTS; Bregma -13.68 to -14.60) were identified using landmarks describe by 
Paxinos and Watson (Paxinos and Watson 1998) under dark field microscopy using a Nikon 80i 
microscope fitted with a camera and rhodamine filter. Each area was traced under fluorescent 
illumination and, with exposure times held constant, mean intensity of GFAP immunoreactivity 
(GFAP-ir) within the outlined area was determined using NIS-Elements AR software 3.2 (Nikon). 
GFAP-ir mean intensity was assessed in rostral, middle, and caudal levels of the AP and in the 
caudal and middle levels of the NTS from each animal, with levels matched between animals. 




Experiment 2: Furosemide Effects on Measures of Body Fluid Balance and Behavioral 
Responses  
Experiment 2 assessed physiological and behavioral responses by OIL- and EB- treated rats (OIL, 
n = 4; EB, n = 5) given ISO and FURO treatment in a within subjects design using the multiple 
18-24 h protocol as shown (Figure 7). Within the hormone groups, each rat served as its own 
control, receiving ISO treatment on week 1 and FURO treatment weekly for three weeks 
thereafter. After each treatment, rats were tested for urinary sodium and volume excretion and 
water and salt intake. 
 
Figure 7. Timeline of multiple 18-24 h FURO treatments protocol in a within subjects 
design. 
 
One week prior to testing, OIL- and EB- treated rats were weighed and placed in metabolic cages 
without food for 24 hours to adapt them to testing procedures and to collect baseline urine values. 
At the end of the 24 hours, rats were given 3-hr access to deionized water and 0.5 M NaCl (salt) 
in graduated drinking tubes to adapt them to the intake test. Following adaptation, rats were 
returned to home cages with ad libitum access to food and water. One week later, rats underwent 
ISO treatment on day 3 as described in the multiple 18-24 h FURO or ISO protocol (Figure 6). 
After each injection, rats were weighed and returned to metabolic cages without food or water. 
Urine was collected one hour after the first injection and again one hour after the second 
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injection. Rats remained in metabolic cages 18-24 h (i.e. until day 4) after the second injection 
with ad libitum access to water but no food. Urine was collected the following morning and water 
intake and body weight were recorded.  
Between 09:00 – 12:00, rats underwent a two-hour two-bottle intake test. Intakes of salt and 
water were recorded after two hours, then rats were returned to home cages with ad libitum 
access to food and water. This procedure was repeated at weekly intervals for three additional 
weeks but with FURO injections on these subsequent weeks. Urinary sodium and potassium 
concentration was assessed using an ion-sensitive electrode system (EasyLyte) as described. 
 
Experiment 3: Furosemide Effects on Synaptic Proteins  
Experiment 3 investigated calcium calmodulin kinase II protein expression in the hindbrain dorsal 
vagal complex in separate groups of OIL- and EB- treated rats that were given FURO treatment 
using the single 18-24 h FURO protocol (ISO: OIL n = 6; EB, n = 6; FURO: OIL n = 7; EB, n = 
6) or the multiple 18-24 h FURO protocol (ISO: OIL n = 7; EB, n = 7; FURO: OIL n = 7; EB, n = 
7) as described (Figures 5 and 7). 
Termination, and Tissue Collection 
After a single 18-24 h or multiple 18-24 h treatment with FURO or ISO, rats were anesthetized 
with carbon dioxide (CO2; 1.5 -2 L/min) and decapitated. Trunk blood was collected into 
heparinized tubes for analysis of plasma protein, sodium, and potassium concentration, with 
aliquots collected into micro-hematocrit capillary tubes for analysis of hematocrit as described in 
experiment 1. The brain was rapidly removed, frozen on dry ice, and stored at -80° C. Uteri were 





Frozen brains were removed from -80°C freezer and transferred into a cryostat at -12°C for 
blocking. A hindbrain section (~500 µm) containing the dorsal vagal complex was located by 
approximating stereotaxic coordinates according to Paxinos and Watson (Paxinos and Watson 
1998). With the brain on its ventral surface, a single sided razor blade was used to cut the spinal 
cord at approximately Bregma -16 and across the primary fissure of the cerebellum between the 
5th and 6th lobules at approximately Bregma -12. Tissue punches from the dorsal vagal complex 
were taken from hindbrain sections using micro-punches (<1mm I.D.). Punches were weighed 
and stored in Eppendorf tubes at -80°C. Tissue punches were homogenized on ice in triple-
detergent lysis buffer (Vargas 2005) using a Sonic Dismembrator (Model 100) set at 1. Samples 
were centrifuged at 12,000 rpm for 30 minutes at 4°C and the supernatant transferred into new 
tubes. Protein concentration was determined using a bicinchoninic acid assay (BCA assay) where 
bovine serum albumin (BSA; 1mg/ml) was used for the standard curve preparation. The total 
protein concentrations were measured at 570 nm using a Bio Tek Synergy 2 microplate reader 
and Gen 5 1.11 imager software (BioTek Instruments, Inc., Winooski, VT, USA). 
Equal amount of protein (20µg) from each sample was transferred into a micro-tube with 5X 
modified Laemmli buffer (pH 6.8) with loading dye (0.25 M Tris HCl; 10% sodium dodecyl 
sulfate; 10mM dithithritol; 30% glycerol; 0.05% bromphenol blue; 50 µL/mL β–
mercaptoethanol) and centrifuged for 30s. Samples were denatured by boiling in a thermocycler 
(Simpli Amp) at 99.9°C for 10 minutes. Samples and protein ladder were electrophoresed on 12% 
acrylamide gels in 1X running buffer at 50V for 20 minutes and 110 volts for 2.5 hours.  
Proteins were electrophoretically transferred at 100 volts for 50 minutes onto low fluorescent 
polyvinylidene difluoride (PVDF) membrane, pre-soaked in 20% methanol. Blots were blocked 
at room temperature for 2 hours in 5% bovine serum albumin (BSA)-1X Tris-buffered saline with 
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0.1 % Tween (TBST). After blocking, blots were rinsed with 1X TBST and incubated overnight 
at 4°C on a rocker in fresh 5% BSA-TBST containing one of the following commercially 
available primary antibodies: glial fibrillary acidic protein (Millipore mouse anti-GFAP; 1:6000), 
calcium calmodulin kinase (Thermo Fisher mouse anti CamKII; 1:1000), or β-actin (#4970; Cell 
Signaling rabbit anti-β-actin; 1:1000). The next day, blots were washed 3X for 10 minutes each 
with 1X TBST. Blots were incubated at 25°C on a rocker for 2 hours in secondary antibodies 
(Amersham ECL Plex goat anti-mouse or anti-rabbit IgG, Cy5; 1:2500 or Cy3; 1:2500) followed 
by additional washes with 1X TBST (6X for 10 minutes each).  
Image Analysis 
Blots were imaged using the GE Health Care Typhoon Scanner 9410. Semi-quantitative analysis 
of immunoblots were performed using freeware NIH ImageJ software (National Institutes of 
Health, Bethesda, MD) using β-actin as loading control. 
 
Statistical Analysis 
All data are presented as means ± S.E. Statistica software (StatSoft) was used for all analyses. 
The difference between means was considered to be significant when P<0.05; the magnitude of 
the difference between groups was assessed using effect size (partial eta squared, Ƞp). 
Comparisons of significant main effects or interactions were made using two-tailed Fisher’s least-
significant difference (LSD) tests. For experiment 1, three-way ANOVA with hormone (OIL, 
EB), drug (ISO, FURO) and frequency (2 h, single 18-24 h) as factors was used to analyze 
GFAP-ir in rostral, middle, and caudal sections from the AP and in the caudal and middle 
sections from the NTS.  
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For experiment 2, the change in body weight in OIL or EB treated rats from day 3 to day 1, given 
multiple OIL/EB treatments was analyzed using a two-way ANOVA with hormone (OIL, EB) 
and week (week 1, week 2, week 3, week 4) as factors, repeated for week. Uterine weight 
normalized to body weight was analyzed using a t-test. Water and salt intake by OIL or EB 
treated rats after FURO/ISO was normalized to body weight by dividing the volume of intake by 
the body weight in 100 grams. Two-way ANOVA with hormone (OIL, EB) and week (week 1, 
week 2, week 3, week 4) as factors, repeated for week, was used to analyze the change in body 
weight after FURO/ISO treatment, urine volume, overnight urine volume, overnight urine sodium 
excretion, overnight urine potassium excretion, overnight urine osmolality, water, salt, and 
overnight water intake. Two-way ANOVA with hormone (OIL, EB) and week (week 2, week 3, 
week 4) as factors, repeated for week, was used to analyze urinary sodium excretion, urinary 
potassium excretion, urine osmolality, water balance, and sodium balance.  
For experiment 3, the change in body weight in OIL or EB treated rats from day 3 to day 1, given 
multiple OIL/EB treatments was analyzed using a two-way ANOVA with hormone (OIL, EB) 
and week (week 1, week 2, week 3) as factors, repeated for week. Uterine weight normalized to 
body weight was analyzed using a t-test. Three-way ANOVA with hormone (OIL, EB), drug 
(ISO, FURO) and week (week 1, week 2, week 3) as factors, repeated for week, was used to 
analyze the change in body weight after FURO/ISO treatment and overnight water intake 
normalized to body weight. Three-way ANOVA with hormone (OIL, EB), drug (ISO, FURO), 
and week (week 0, week 1, week 2) as factors, repeated for week, was used to analyze water and 
salt intake normalized to body weight. Two-way ANOVA with hormone (OIL, EB) and drug 
(ISO, FURO) was used to analyze hematocrit, plasma protein, plasma sodium, plasma potassium, 
and plasma osmolality. The change in protein expression from control (ISO) of GFAP normalized 
to beta-actin expression was analyzed using a three-way ANOVA with hormone (OIL, EB), drug 
(ISO, FURO), and frequency (single 18-24 hr, multiple 18-24 hr) as factors. Finally, the change 
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in protein expression from control (ISO) of CaMKII normalized to beta-actin expression was 
analyzed using a two-way ANOVA with hormone (OIL, EB) and drug (ISO, FURO) as factors 








Experiment 1: Furosemide Effects on Astrocytes in the Dorsal Vagal Complex 
Area Postrema 
GFAP-ir in the area postrema (AP) (Figures 7-12) differed between FURO and ISO treated rats 
with the effect of hormone depending on level of AP.  
Three-way ANOVA revealed a main effect of drug [F(1,24)= 6.3, p<0.05, 𝜂𝑝
2 = 0.21] on GFAP-ir 
in the caudal AP (Figure 8), with FURO decreasing GFAP-ir independent of hormone or 
protocol. There were no main effects of hormone or protocol, and no interactions.  
Three-way ANOVA revealed a main effect of drug [F(1,23)= 4.6, p<0.05, 𝜂𝑝
2 = 0.17] on GFAP-ir 
in the middle AP (Figure 10), with FURO decreasing GFAP-ir independent of hormone or 
protocol. Here, too, there were no main effects of hormone or protocol, and no interactions. 
Three-way ANOVA revealed a main effect of drug [F(1,22) = 16.8, p<0.001, 𝜂𝑝
2 = 0.43] on 
GFAP-ir in the rostral AP (Figure 12), with FURO decreasing GFAP-ir independent of hormone 
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Figure 8. Schematic and representative photomicrographs of GFAP immunoreactivity (GFAP-ir) in 
the caudal area postrema (AP). (A) Schematic representation of a coronal section through the rat 
hindbrain highlighting AP (red shading); adapted from Paxinos and Watson 1998. Area outlined in black is 
enlarged to the right. (B) Representative fluorescent photomicrographs of GFAP (red staining) in the caudal 
AP of OVX rats given OIL vehicle (OIL) or estradiol benzoate (EB) as described. Rate were given s.c. 
injections of 0.15 M NaCl (ISO) or furosemide (FURO) and then terminated 2 hours or 18-24 hours later. 














































Figure 9. Mean GFAP immunoreactivity (GFAP-ir) in the caudal area postrema (AP). 
GFAP-ir in the caudal AP of OVX rats given OIL vehicle (OIL) or estradiol benzoate (EB) 
treatment and s.c. injections of 0.15 M NaCl (ISO: OIL, white bars; EB, dotted bars) or 
furosemide (FURO: OIL, grid bars; EB, black bars) and terminated 2 hours or 18-24 hours later. 
There was a significant effect of drug, with GFAP-ir in FURO treated rats less than that in ISO 
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Figure 10. Schematic and representative photomicrographs of GFAP immunoreactivity (GFAP-ir) in 
the middle area postrema (AP). (A) Schematic representation of a coronal section through the rat 
hindbrain highlighting AP (red shading) adapted from Paxinos and Watson 1998. Area outlined in black is 
enlarged to the right. (B) Representative fluorescent photomicrographs of GFAP (red staining) in the 
middle AP of OVX rats given OIL vehicle (OIL) or estradiol benzoate (EB) and s.c. injections of 0.15 
M NaCl (ISO) or furosemide (FURO) and then terminated 2 hours or 18-24 hours later. Scale bar, 100 µm.  
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Figure 11. Mean GFAP immunoreactivity (GFAP-ir) in the middle area postrema (AP). 
GFAP-ir in the middle AP of OVX rats given OIL vehicle (OIL) or estradiol benzoate (EB) and  
s.c. injections of 0.15 M NaCl (ISO: OIL, white bars; EB, dotted bars) or furosemide (FURO: 
OIL, grid bars; EB, black bars) and terminated 2 hours or 18-24 hours later. There was a 
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Figure 12. Schematic and representative photomicrographs of GFAP- immunoreactivity (GFAP-ir) in 
the rostral area postrema (AP). (A) Schematic representation of a coronal section through the rat 
hindbrain highlighting AP (red shading) adapted from Paxinos and Watson 1998. Area outlined in black is 
enlarged to the right. (B) Representative fluorescent photomicrographs of GFAP (red staining) in the rostral 
AP of OVX rats given OIL vehicle (OIL) or estradiol benzoate (EB) and s.c. injections of 0.15 M NaCl 















































Figure 13. Mean GFAP immunoreactivity (GFAP-ir) in the rostral area postrema (AP). 
GFAP-ir in the rostral AP of OVX rats given OIL vehicle (OIL) or estradiol benzoate (EB) and 
s.c. injections of 0.15 M NaCl (ISO: OIL, white bars; EB, dotted bars) or furosemide (FURO: 
OIL, grid bars; EB, black bars) and then terminated 2 hours or 18-24 hours later. There was a 
significant effect of drug, with GFAP-ir in FURO treated rats less than that in ISO treated rats.  
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Nucleus of the Solitary Tract  
Three-way ANOVA revealed a main effect of protocol [F(1,32) = 5.5, p<0.05, 𝜂𝑝
2 = 0.15] on 
GFAP-ir in the caudal NTS (Figure 14), as well as a protocol by drug interaction [F(1,32) = 13.6, 
p<0.001, 𝜂𝑝
2 = 0.30]. Comparisons of this interaction revealed GFAP-ir was greater in the 18-24 h 
FURO protocol (ps< 0.05, 0.001, 0.05, 0.01). There were no main effects of hormone or drug and 
no other interactions.  
Three-way ANOVA revealed a main effect of drug [F(1,28) = 5.4, p<0.05, 𝜂𝑝
2 = 0.16] on GFAP-
ir in the middle NTS (Figure 16), as well as a protocol by drug interaction [F(1,28) = 12.4, 
p<0.01, 𝜂𝑝
2 = 0.31]. Comparisons of this interaction revealed GFAP-ir was greater in the 18-24 h 





B OIL ISO EB ISO 
OIL FURO EB FURO 
OIL ISO EB ISO 
OIL FURO EB FURO 
A 






















Figure 14. Schematic and representative photomicrographs of GFAP immunoreactivity (GFAP-ir) in 
the caudal nucleus of the solitary tract (NTS). (A) Schematic representation of a coronal section through 
the rat hindbrain highlighting the caudal NTS (grey shading) adapted from Paxinos and Watson 1998. Area 
outlined in black is enlarged to the right; red shading indicates the area from which measurements were 
taken. (B) Representative fluorescent photomicrographs of GFAP (red staining) in the caudal NTS of OVX 
rats given OIL vehicle (OIL) or estradiol benzoate (EB) and s.c. injections of 0.15 M NaCl (ISO) or 









































Figure 15. Mean GFAP immunoreactivity (GFAP-ir) in the caudal nucleus of the solitary 
tract (NTS). GFAP-ir in the caudal NTS of OVX rats given OIL vehicle (OIL) or estradiol 
benzoate (EB) and s.c. injections of 0.15 M NaCl (ISO: OIL, white bars; EB, dotted bars) or 
furosemide (FURO: OIL, grid bars; EB, black bars) and then terminated 2 hours or 18-24 hours 
later. There was a significant effect of protocol and a protocol by drug interaction.
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Figure 16. Schematic and representative photomicrographs of GFAP immunoreactivity (GFAP-ir) in 
the middle nucleus of the solitary tract (NTS). (A) Schematic representation of a coronal section through 
the rat hindbrain highlighting the middle NTS (grey shading) adapted from Paxinos and Watson 1998. Area 
outlined in black is enlarged to the right; red shading indicates the area from which measurements were 
taken. (B) Representative fluorescent photomicrographs of GFAP (red staining) in the middle NTS of OVX 
rats given OIL vehicle (OIL) or estradiol benzoate (EB) and s.c. injections of 0.15 M NaCl (ISO) or 









































Figure 17. Mean GFAP immunoreactivity (GFAP-ir) in the middle nucleus of the solitary 
tract (NTS). GFAP-ir in the middle NTS of OVX rats given OIL vehicle (OIL) or estradiol 
benzoate (EB) and s.c. injections of 0.15 M NaCl (ISO: OIL, white bars; EB, dotted bars) or 
furosemide (FURO: OIL, grid bars; EB, black bars) and then terminated 2 hours or 18-24 hours 




Experiment 2: Furosemide Effects on Measures of Fluid Balance and Behavioral Responses 
Efficacy of Recurrent Estrodial Benzoate Treatment 
Body weight (Figure 17) of ovariectomized rats differed between OIL- and EB-treated rats during 
the hormone regimen prior to drug treatment. Two-way rm-ANOVA revealed a main effect of 
hormone [F(1,7) = 7.6, p<0.05, 𝜂𝑝
2 = 0.52] on the change in body weight from day 3 to day 1 but 
no main effect of time or interactions.  
Uterine weight normalized to body weight (Figure 18) in OVX rats was significantly greater after 
EB treatment compared to that after OIL treatment (t = -7.86; p<0.001).  
 
Figure 18. Efficacy of recurrent estradiol benzoate (EB) treatment on body weight: Change 
in body weight (g) during the hormone treatment regimen in OIL vehicle (OIL; white bars; n=4) 
treated and estradiol benzoate-treated (EB; black bars; n=5) OVX rats prior to injection with 





Figure 19. Efficacy of estradiol benzoate (EB) treatment on uterine weight: Uterine weight 
(mg) in OIL vehicle-treated  (OIL; white bar) and estradiol benzoate-treated (EB; black bar) OVX 
rats sacrificed 18-24 hours after injection with FURO (FURO) or 0.15 M NaCl (ISO) on day 4. * 
= significantly different from OIL. 
 
Efficacy of Multiple Furosemide Treatments 
Two-way rm-ANOVA revealed a main effect of time [F(1,3) = 134.1; p<0.001, 𝜂𝑝
2= 0.95] and no 
hormone by time interaction on body weight loss (Figure 19) in OVX rats. Comparisons of the 
body weight loss over time revealed that, independent of hormone treatment, weight loss in week 
one (the ISO treatment week) was significantly less (ps<0.001) than that in all other weeks (the 
FURO treatment weeks). Body weight loss during the FURO treatment weeks were not different 





Figure 20. Efficacy of multiple furosemide (FURO) treatments on body weight: Body weight 
loss by OIL- (white bars; n = 4) and EB- (black bars; n = 5) treated rats two hours after injection 
with furosemide (FURO) or 0.15 M NaCl (ISO) treatment in a within subjects design using the 
multiple 18-24 h protocol. Within the hormone groups, each rat served as its own control, 
receiving ISO treatment for one week and then FURO treatment weekly for three weeks. * = 
significantly less from all other weeks; ps<0.001. 
 
Urinary Excretion 
In rats given multiple FURO treatments in a within subjects design, two-way rm-ANOVA 
revealed a main effect of week [F(1,3) = 198.2; p<0.001, 𝜂𝑝
2 = 0.97] on urine volume (Figure 20). 
Pairwise comparisons of the main effect of week revealed that urine volume in week 1, the week 
of ISO treatment, was significantly less than that in weeks 2-4, the FURO treatment weeks (ps< 
0.001). Urine volume, and therefore urine sodium and potassium excretion, were negligible after 
ISO. Accordingly, analyses of urinary sodium and potassium excretion and urine osmolality were 
conducted only after FURO treatment (i.e., weeks 2-4). Two-way rm-ANOVA revealed a main 
effect of week on urinary sodium excretion (Figure 21) [F (2, 14) = 11.8, p<0.001, 𝜂𝑝




























urinary potassium excretion (Figure 22) [F (2, 14) = 9.0, p<0.01, 𝜂𝑝
2 = 0.56], and urine osmolality 
(Figure 0) [F (2, 14) = 5.3, p<0.05, 𝜂𝑝
2 = 0.43]. Planned comparisons revealed that sodium 
excretion (ps<0.001-0.05) and potassium excretion (ps<0.01-0.05) was significantly greater on 
week 3, the second week of furosemide treatment compared to other weeks. In all cases, pairwise 
comparisons revealed no effects of hormone, nor were there interactions between hormone and 
week. 
 
Figure 21. Urine volume: Urine output (mL) by OIL- (white bars; n = 4) and EB- (black bars; n 
= 5) treated rats two hours after FURO and ISO treatment in a within subjects design. Within the 
hormone groups, each rat served as its own control, receiving ISO treatment on week 1 and 



























Figure 22. Urine sodium (Na+) excretion: Urine Na+ excretion by OIL- (white bars; n = 4) and 
EB- (black bars; n = 5) treated rats two hours after FURO treatment in a within subjects design. 
Within the hormone groups, each rat served as its own control. Sodium excretion was 
significantly greater on week 3, the second week of furosemide treatment compared to other 
weeks (ps<0.001-0.05). Urine volume, and therefore urine sodium and potassium excretion, were 
negligible after ISO. Accordingly, analyses of urinary sodium and potassium excretion and urine 

































Figure 23. Urine potassium (K+) excretion: Urine K+ excretion by OIL- (white bars; n = 4) and 
EB- (black bars; n = 5) treated rats two hours after FURO treatment in a within subjects design. 
Within the hormone groups, each rat served as its own control. Potassium excretion was 
significantly greater on week 3, the second week of furosemide treatment compared to other 
weeks (ps<0.01-0.05). Urine volume, and therefore urine sodium and potassium excretion, were 
negligible after ISO. Accordingly, analyses of urinary sodium and potassium excretion and urine 


































Figure 24. Urine osmolality: Urine osmolality (mmol/kg) in OIL- (white bars; n = 4) and EB- 
(black bars; n = 5) treated rats two hours after FURO treatment in a within subjects design. 
Within the hormone groups, each rat served as its own control. Urine volume, and therefore urine 
sodium and potassium excretion, were negligible after ISO. Accordingly, analyses of urinary 
sodium and potassium excretion and urine osmolality were conducted only after FURO treatment 
(i.e., weeks 2-4). 
 
Overnight Urinary Excretion 
Two-way rm-ANOVA revealed no main effects or interactions for overnight urine volume, 






































Figure 25. Overnight urine volume: Overnight urine output (mL) by OIL- (white bars; n = 4) 
and EB- (black bars; n = 5) treated rats given FURO or ISO treatment in a within subjects design 
using the multiple 18-24 h protocol. Within the hormone groups, each rat served as its own 
control, receiving ISO treatment on week 1and FURO treatment on week 2-4. Urine was 








































Figure 26. Overnight sodium (Na+) excretion: Overnight urine Na+ excretion (mmol) by OIL- 
(white bars; n = 4) and EB- (black bars; n = 5) treated rats given FURO or ISO treatment in a 
within subjects design using the multiple 18-24 h protocol. Within the hormone groups, each rat 
served as its own control, receiving ISO treatment on week 1and FURO treatment on week 2-4. 











































Figure 27. Overnight potassium (K+) excretion: Overnight urine K+ excretion (mmol) by OIL- 
(white bars; n = 4) and EB- (black bars; n = 5) treated rats given FURO or ISO treatment in a 
within subjects design using the multiple 18-24 h protocol. Within the hormone groups, each rat 
served as its own control, receiving ISO treatment on week 1and FURO treatment on week 2-4. 








Figure 28. Overnight urine osmolality: Overnight urine osmolality (mmol/kg) by OIL- (white 
bars; n = 4) and EB- (black bars; n = 5) treated rats given FURO or ISO treatment in a within 
subjects design using the multiple 18-24 h protocol. Within the hormone groups, each rat served 
as its own control, receiving ISO treatment on week 1and FURO treatment on week 2-4. Urine 
was collected 18-24 hour after injection. There were no main effects or interactions. 
 
Overnight Water Intake 
In OIL or EB treated rats given multiple FURO treatments in a within subjects design, two-way 
rm-ANOVA revealed a main effect of week [F (3, 21) = 6.1, p<0.01, 𝜂𝑝
2 = 0.46] on overnight 
water intake normalized to body weight (Figure 28). Pairwise comparisons of overnight water 
intake over time revealed that water intake was significantly less (ps<0.01-0.05) on week 1 
compared to week 2-4 (FURO treatment). Overnight water intake on the FURO treatment weeks 











































Figure 29. Overnight water intake: Overnight water intake/100 g body weight (BW) by OIL- 
(white bars; n = 4) and EB- (black bars; n = 5) treated rats given FURO and ISO treatment in a 
within subjects design using the multiple 18-24 h protocol. * = Overnight water intake on week 1 



















































Sodium and Water Balance 
Two-way rm-ANOVA revealed a significant main effect of week [F(2,14) = 9.2, p<0.01, 𝜂𝑝
2 = 
0.57] on sodium balance (Figure 29). Pairwise comparisons revealed a greater decrement in 
sodium balance on week 3 (ps<0.01-0.05) compared to weeks two or four. There were no effects 
for the calculated water balance (Figure 30). 
 
 
Figure 30. Sodium balance: Sodium balance (intake-output) by OIL- (white bars; n = 4) and EB- 
(black bars; n = 5) treated rats given FURO treatment in a within subjects design using the 
multiple 18-24 h protocol. * = Sodium balance on week 3 was significantly less than that on week 




Figure 31. Water balance: Water balance (intake-output) by OIL- (white bars; n = 4) and EB- 
(black bars; n = 5) treated rats given FURO treatment in a within subjects design using the 
multiple 18-24 h protocol. There were no main effects or interactions. 
 
 
2 h Salt Intake 
In OIL- or EB-treated rats given multiple FURO treatments in a within subjects design, two-way 
rm-ANOVA revealed a significant main effect of week [F (3, 18) = 17.7, p<0.001, 𝜂𝑝
2 = 0.75] on 
salt intake (Figure 31) normalized to body weight, but no main effect of hormone or interactions. 
Planned comparisons revealed that independent of hormone, salt intake on week 1 (the ISO week) 
was less than that on weeks 2, 3, or 4 (the FURO weeks) by OIL- (ps<0.05, 0.001, 0.01) and EB- 


























Figure 32. 2 h Salt Intake: Salt intake/100 g body weight (BW) during a two hour test by OIL- 
(white bars; n = 4) and EB- (black bars; n = 5) treated rats. Testing began on day 4, 18-24 hour 
after the second injection with 0.15 M NaCl (ISO) or furosemide (FURO) in a within-subjects 
design using the multiple 18-24 h protocol. * = Salt intake on week 1 was significantly less than 
that on week 2-4. 
 
 
2 h Water Intake 
In OIL or EB treated rats given multiple FURO treatments in a within subjects design, two-way 
rm-ANOVA revealed a main effect of week [F (3, 21) = 7.3, p<0.01, 𝜂𝑝
2 = 0.51] on water intake 
normalized to body weight (Figure 32), no main effect of hormone, or interactions. Planned 
comparisons of the main effect of week revealed that rats drank less water during week 1 (the 





























Figure 33. 2 h Water intake: Water intake/100 g body weight (BW) during a two hour test by 
OIL- (white bars; n = 4) and EB- (black bars; n = 5) treated rats. Testing began on day 4, 18-24 
hour after the second injection with 0.15 M NaCl (ISO) or furosemide (FURO) in a within-
subjects design using the multiple 18-24 h protocol. * = Water intake on week 1 was significantly 





































Experiment 3: Furosemide Effects on Synaptic Proteins 
Single 18-24 Hour Furosemide 
Efficacy of Estrodial Benzoate Treatment 
The change in body weight (Table 1) of OVX rats differed between OIL and EB treated rats over 
the hormone regimen prior to drug treatment, and was significantly less in OVX rats after EB 
treatment compared to that in OIL-treated rats (t = 10.48; p<0.001). Uterine weight (Table 1) in 
OVX rats was significantly greater after EB treatment compared to that in OIL-treated rats (t = -
12.4; p<0.001). 
 
Table 1. Efficacy of estradiol benzoate (EB) treatment. Change in body weight (g) during the 
hormone treatment regimen (day 3 weight-day 1 weight) in oil vehicle (OIL; n=15) treated and 
estradiol benzoate-treated (EB; n=12) OVX rats prior to injection with a single 18-24 h 
furosemide (FURO) or 0.15 M NaCl (ISO). Uterine weights (mg/100 g body weight) were 
assessed at sacrifice on day 4, twenty-four hours after a single 18-24 h FURO or ISO. * = 
significantly different from OIL. 
 
 Change in body  
weight (g) 
Uterine weight  
(mg/100 g body weight) 
OIL 8.4 + 0.8 10.6 + 0.4 
EB -5.3 + 1.0* 27.8 + 1.4* 
  
 
Efficacy of a Single Furosemide Treatment 
Body weight loss (Table 2) differed in OVX rats given FURO or ISO. Two-way ANOVA 
revealed a main effect of drug [F(1,23) = 178.0; p<0.001, 𝜂𝑝
2= 0.89] on the change in body weight 
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with greater weight loss 2 hours after FURO. There was no main effect of hormone and no 
interaction.  
There was no effect of hormone or drug on plasma sodium concentration in OVX rats (Table 2), 
and no interaction between factors.  
Two- way ANOVA revealed a main effect of drug on plasma protein concentration [F(1,23) = 
17.7; p<0.001, 𝜂𝑝
2= 0.43], hematocrit [F(1,23) = 13.5; p<0.01, 𝜂𝑝
2= 0.37], plasma potassium 
concentration [F(1,23) = 10.7; p<0.01, 𝜂𝑝
2= 0.32], and plasma osmolality [F(1,23) = 5.7; p<0.05, 
𝜂𝑝
2= 0.20] assessed on day 4, twenty four hours after FURO or ISO, with greater plasma protein, 
hematocrit, and plasma osmolality (Table 2) after FURO independent of hormone. Plasma 
potassium concentration (Table 2) was decreased after FURO. There was no effect of hormone 
and no interaction for any of these measures. 
 
Table 2. Efficacy of furosemide after a single 18-24 h treatment. Body weight loss (g) in oil 
vehicle-treated (OIL; n=6-9/condition) and estradiol benzoate-treated (EB; n=6/condition) OVX 
rats two hours after a single 18-24 h furosemide (FURO) or 0.15 M NaCl (ISO) treatment. Plasma 
protein concentration (pPro; g/dL), hematocrit, plasma Na+ concentration (pNa+; mMol/L plasma 
water), plasma K+ concentration (pK+; mMol/L plasma water), and plasma osmolality (mmol/kg) 
were assessed at sacrifice on day 4, twenty four hours after FURO or ISO. # = significantly 
different from ISO. 
 
 Body weight loss  pPro  Hematocrit 
            
 ISO  FURO#  ISO  FURO#  ISO  FURO# 
OIL -5.5 + 1.1  -17.6 + 0.6  6.5 + 0.2  6.9 + 0.1  45.9 + 1.3  51.7 + 0.8 
EB -6.0 + 0.7  -15.0 + 0.5  6.5 + 0.1  7.3 + 0.2  48.1 + 0.7  50.0 + 1.0 
            
 pNa+  pK+  pOsm 
            
 ISO  FURO  ISO  FURO#  ISO  FURO# 
OIL 147.0 + 0.5  142.4 + 1.6  5.5 + 0.2  4.7 + 0.2  371.3 + 9.2  405.1 + 11.2 





Multiple 18-24 Hour Furosemide  
Efficacy of Recurrent Estrodial Benzoate Treatment 
Body weight change (Figure 33) in OVX rats prior to drug treatment differed between OIL- and 
EB-treated rats throughout the protocol. Two-way rm-ANOVA revealed a main effect of 
hormone [F(1,52) = 80.4; p<0.001, 𝜂𝑝
2= 0.76] on the change in body weight, with OIL-treated rats 









Figure 34. Efficacy of recurrent estradiol benzoate (EB) treatment on body weight: Change 
in body weight (g) during the hormone treatment regimen in OIL vehicle (OIL; white bars; n=14) 
treated and estradiol benzoate-treated (EB; black bars; n=14) OVX rats prior to injection with 




































































































Uterine weight (Figure 34) in OVX rats was significantly greater after EB treatment compared to 










Figure 35. Efficacy of estradiol benzoate (EB) treatment on uterine weight: Uterine weight 
(mg) per 100 g body weight (BW) in OIL vehicle-treated (OIL; white bar) and estradiol benzoate-
treated (EB; black bar) OVX rats sacrificed on week 3, 18-24 hours after injection with 










Efficacy of Multiple Furosemide Treatment 
Three-way rm-ANOVA revealed a main effect of hormone [F(1,24) = 7.5; p<0.05, 𝜂𝑝
2= 0.24], a 
main effect of drug [F(1,24) = 507.7; p<0.001, 𝜂𝑝
2= 0.95], and a hormone by week interaction 
[F(1,48) = 4.3; p<0.05, 𝜂𝑝
2= 0.15] on body weight loss (Figure 35) two hours after injection with 
FURO or ISO treatment using the multiple 18-24 h protocol. Pairwise comparisons of the 
interaction revealed greater weight loss after FURO in OIL-treated rats compared to EB-treated 
rats during weeks 1 and 2 (ps<0.001-0.05) that did not persist in week 3. 
 
Figure 36. Efficacy of multiple furosemide (FURO) treatments on body weight: Body weight 
loss by OIL- (ISO: white bars, n = 7; FURO: grid bars, n=7) and EB- (ISO: dotted bars, n=7; 
FURO: black bars, n = 7) treated rats two hours after injection with FURO or 0.15 M NaCl (ISO) 
using the multiple 18-24 h protocol. There was a significant effect of drug, with greater weight 
loss after FURO than that after ISO and a significant effect of hormone, with greater weight loss 
in OIL-treated rats, independent of drug or week. Finally, there was a hormone by week 
interaction, with significantly greater weight loss in OIL- treated rats compared to EB-treated rats 
































The average body weight loss over weeks 1-3 also was calculated to facilitate comparisons with 
the single 18-24 h FURO and multiple 18-24 h FURO protocols (Table 2, Table 3). Two-way 
ANOVA of the average body weight loss revealed a main effect of hormone [F(1,24) = 7.5; 
p<0.05, 𝜂𝑝
2= 0.24] and a main effect of drug [F(1,24) = 507.7; p<0.001, 𝜂𝑝
2= 0.95], with greater 
weight loss after FURO, but no main effect of hormone and no interaction.  
Two- way ANOVA revealed a main effect of hormone on plasma sodium concentration [F(1,20) 
= 5.5; p<0.05, 𝜂𝑝
2= 0.22], plasma protein concentration [F(1,20) = 19.1; p<0.001, 𝜂𝑝
2= 0.49], and 
hematocrit [F(1,24) = 13.5; p<0.01, 𝜂𝑝
2= 0.36] assessed at sacrifice on day 4, twenty four hours 
after the final FURO or ISO treatment (Table 3). EB-treated rats had greater plasma sodium and 
plasma protein concentrations independent of drug treatment, while hematocrit was less in EB-
treated rats independent of drug treatment. There was no effect of hormone or drug on plasma 
potassium concentration or plasma osmolality in OVX rats, and no interaction between factors. 
 
Table 3. Efficacy of furosemide after multiple treatments. Body weight loss (g) in oil vehicle-
treated (OIL; n=6-9/condition) and estradiol benzoate-treated (EB; n=6/condition) OVX rats two 
hours after injection with a single 18-24 h furosemide (FURO) or 0.15 M NaCl (ISO) treatment. 
Plasma protein concentration (pPro; g/dL), hematocrit, plasma Na+ concentration (pNa+; mMol/L 
plasma water), plasma K+ concentration (pK+; mMol/L plasma water), and plasma osmolality 
(mmol/kg) were assessed at sacrifice on day 4, twenty four hours after 3rd FURO or ISO. # = 
significantly different from ISO.  
 
 Body weight loss  pPro  Hematocrit 
            
 ISO  FURO#  ISO  FURO#  ISO  FURO# 
OIL -3.1 + 0.4  -15.4 + 0.5  6.9 + 0.1  6.9 + 0.1  54.8 + 1.1  54.4 + 1.7 
EB -2.2 + 0.3  -13.5 + 0.6  7.6 + 0.2  8.2 + 0.3  47.8 + 0.7  51.1 + 1.5 
            
 pNa+  pK+  pOsm 
            
 ISO  FURO  ISO  FURO#  ISO  FURO# 
OIL 146.3 + 1.9  140.3 + 1.1  7.9 + 0.9  6.7 + 0.8  397.5 + 16.8  362.8 + 8.2 





Overnight Water Intake 
Three-way rm-ANOVA on overnight water intake (Figure 36) revealed a main effect of drug [F 
(1, 22) = 11.6, p<0.01, 𝜂𝑝
2 = 0.34] by OIL or EB treated rats given multiple FURO or ISO 









Figure 37. Overnight water intake: Overnight water intake/100 g body weight (BW) by OIL- 
(ISO: white bars, n = 7; FURO: grid bars, n=7) and EB- (ISO: dotted bars, n=7; FURO: black 
bars, n = 7) treated rats given FURO and ISO treatment using the multiple 18-24 h protocol. * = 











































Three-way repeated measures ANOVA revealed a main effect of drug [F (1, 24) = 17.2, p<0.001, 
𝜂𝑝
2 = 0.42], a main effect of time [F (2, 48) = 10.5, p<0.001, 𝜂𝑝
2 = 0.31], and a time by drug 
interaction [F (2, 48) = 8.4, p<0.001, 𝜂𝑝
2 = 0.26] for water intake normalized to bodyweight 
(Figure 37) by OIL or EB treated rats given multiple FURO or ISO treatments. Pairwise 
comparisons of the interaction revealed water intake by OIL treated rats given multiple FURO 
treatments increased after each weekly test (ps<0.05) except for the third test week. Water intake 
by EB treated rats given multiple FURO treatments increased after each weekly test (ps<0.01, 
0.001, 0.05) and the water intake after the third test week was greater than that by OIL treated rats 
of the same week. 
 
Figure 38. 2 h Water Intake: Water intake/100 g body weight (BW) during a two hour test by 
OIL- (white bars; n = 7) and EB- (black bars; n = 7) treated rats. Testing began on day 4, 18-24 
hour after the second injection with 0.15 M NaCl (ISO) or furosemide (FURO) using the multiple 





































Three-way repeated measures ANOVA revealed a main effect of drug [F (1, 23) = 33.7, p<0.001, 
η²= 0.59], a main effect of time [F (2, 46) = 19.0, p<0.001, 𝜂𝑝
2 = 0.45], and a time by drug 
interaction [F (2, 46) = 14.0, p<0.001, 𝜂𝑝
2 = 0.38] for salt intake normalized to bodyweight 
(Figure 38) by OIL or EB treated rats given multiple FURO or ISO treatments. Pairwise 
comparisons of the interaction revealed salt intake increased after each weekly test by OIL 








Figure 39. 2 h Salt Intake: Salt intake/100 g body weight (BW) during a two hour test by OIL- 
(white bars; n = 7) and EB- (black bars; n = 7) treated rats. Testing began on day 4, 18-24 hour 
after the second injection with 0.15 M NaCl (ISO) or furosemide (FURO) using the multiple 18-








Glia Fibrillary Acidic Protein 
Three-way ANOVA revealed a main effect of drug [F (1, 48) = 4.3, p<0.05, 𝜂𝑝
2 = 0.08] on protein 
expression of GFAP after a single and multiple 18-24 h FURO, no main effects of hormone or 
frequency, and no interactions. Planned comparisons revealed that GFAP expression after a single 
18-24 h FURO was significantly less (p<0.05) in EB-treated rats.  
 



























Figure 41. Density of GFAP in the DVC. GFAP density in the DVC of OVX rats given OIL 
(left) or EB (right) and a single treatment with 0.15 M NaCl (ISO; white bars) or furosemide 
(FURO; black bars) and then terminated 18-24 hours later.  
 
Figure 40. Representative immunoblot for GFAP (green) and 
beta actin (red) density in the DVC after a single 18-24 h FURO.  
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Calcium Calmodulin Kinase II 
Single 18-24 h FURO  
Two-way ANOVA on protein expression of GFAP after a single 18-24 h FURO revealed no main 
effects of hormone or drug and no interactions. The change in expression of CaMKII from ISO 
was significantly decreased in EB-treated rats compared to Oil-treated rats (t = 0.892.3; p<0.23). 
 
Calcium Calmodulin Kinase II after a Single 18-24 h FURO 
  
 
Figure 43. Density of CaMKII in the DVC. CaMKII density in the DVC of OVX rats given OIL 
(left) or EB (right) and a single treatment with 0.15 M NaCl (ISO; white bars) or furosemide 

























OIL ISO OIL FURO EB ISO EB FURO
Figure 42. Representative western blot 
for CaMKII (red) and beta actin 
(green) density in the DVC 




Figure 44. Change in CaMKII density in the DVC. CaMKII density in the DVC of OVX rats 
given OIL or EB and a single treatment with furosemide (FURO; OIL, black bar; EB, orange bar) 













Multiple 18-24 h FURO  
Western blot for the protein expression of CaMKII after multiple 18-24 h FURO resulted in weak 
to no signal detection, therefore it was not possible to reliably quantify. Unsuccessful band 
detection may be due to an inappropriate antibody concentration for the level of expression after 
multiple 18-24 h FURO. However, linear range analysis revealed the antibody for CaMKII was 
detectable in whole brain homogenate down to low concentrations of protein. Consideration must 
be given to differences between a whole brain homogenate containing brain areas where CaMKII 
expression may be more pronounced. CaMKII within the DVC may be expressed in low 
concentrations, making detection of changes in CaMKII after multiple 18-24 FURO treatments 
difficult. Western blot technique may not be the optimal technique for detecting proteins 
expressed in extremely low concentrations. 
 
Calcium Calmodulin Kinase II after Multiple 18-24 h FURO 
 OILISO     OILFURO    EBISO     EBFURO  
Figure 45. Representative western blot 
for CaMKII (red) and beta actin 
(green) density in the DVC of rats 
after multiple 18-24 h FURO 
Figure 46. Representative western blot for the linear range 









 Repeated experiences with treatments that produce sodium loss increase sodium intake 
with each subsequent experience, a form of behavioral plasticity that is more pronounced in 
females with EB. We hypothesized that such plasticity occurs within central areas associated with 
the initial detection of sodium loss prior to integration by hypothalamic control centers. We tested 
this idea by first using immunohistochemistry to examine the time course of changes in astrocytes 
in the hindbrain dorsal vagal complex. 
 
GFAP-ir in the Area Postrema 
  In general, astrocyte abundance, as indicated by GFAP-ir, was decreased in the AP 18-24 
hours after FURO treatment. Astrocyte abundance was also decreased in the rostral AP 2 hours 
after FURO independent of hormone treatment. The decrease in astrocytes in the caudal, middle, 
and rostral AP 18-24 hours after FURO (Figs. 9, 11, 13), at the time of salt intake, imply that 
these astrocytes may be sensitive to an osmotic signal associated with hypovolemia and/or 
hyponatremia. Astrocytes in the SFO, another sensory circumventricular organ, show expression 
of a sodium sensitive sodium channel capable of detecting increases in extracellular sodium 
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(Watanabe 2006) and astrocytes in other areas facilitate body water homeostasis by the 
expression of water channels or aquaporins (Roberta 2010). The functional implications of 
sodium channels and aquaporins has yet to be fully understood, but some believe astrocytes 
respond to osmotic shifts by swelling, a response thought to spare neurons from the damaging 
effects of hypertonicity (Schliess 1996). At present, it is unknown if astrocytes in the AP express 
any of these regulatory proteins. Thus whether the sensing capabilities of astrocytes in the AP 
have influence on neural excitability or inhibition is an area of active investigation with many 
questions remaining. 
 The effects of EB on astrocytes depended on level in the AP and were detectable 2 hours 
after FURO. Specifically, astrocyte abundance was decreased in the caudal and middle AP 2 
hours after FURO in rats given EB compared to OIL-treated rats, but this difference was not 
observed in the rostral AP, where astrocyte abundance was decreased in both OIL- and EB-
treated rats. The physiological response to FURO (e.g. increased urinary excretion) is a relatively 
rapid disruption of fluid balance, which activates compensatory cardiovascular and renal 
mechanisms. The loss of astrocytes in the caudal and middle AP at this time point suggests the 
effects of estradiol on astrocytes may promote early detection of such disturbances. The lack of 
an estradiol effect in the rostral AP may simply be due to differences in the astrocyte phenotype 
and/or function at this level of the AP. Alternatively, differential effects according to level within 
the AP may be due to the type of input, whether it is gastrointestinal in the rostral AP or 
cardiovascular in the caudal AP. It is also well known that steroid hormones initiate glial 
reorganization in areas of the brain involved in reproduction (Garcia-Segura 2006) and in 
astrocyte cultures EB inhibits GFAP expression (Rozovsky 2002). Thus, retraction of astrocytes 
in EB-treated rats in the AP may be another way in which hormones confer protection and alter 
the activity of neurons that project to other central areas, thereby initiating a more rapid 
behavioral response to sodium loss by EB-treated rats.  
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 Astrocytes in the AP display unique morphology and functional characteristics compared 
to other astrocytes in that they do not contain some of the adhesion proteins involved in 
membrane formation and association with vascular endothelial cells (Willis 2007). It has yet to be 
determined the role these astrocytes play in neural humoral communication. One theory put 
forward by Willis et al. 2013 proposes that these astrocytes serve as an early response to maintain 
BBB integrity by essentially sensing the ‘threat’, sending out a distress signal, and then 
withdrawing from the site to allow infiltration of macrophages and repair cells. Support for this 
theory can be found in the fact that astrocytes in the AP have a wide variety of receptors for 
neurotransmitters and peptides (Carpenter 1988) and the discovery of immune cells (Goehler 
2006) in the AP. Thus, astrocytes may participate in an immuno-chemosensory role to monitor 
changes in a wide variety of pathways. A specialized astrocyte population residing at the interface 
of central and peripheral communication would make sense given the need for the CNS to 








Figure 47. Glial modulation of neuronal signaling in the DVC to influence salt intake. Top 
figure illustrates glial association with blood vessels and neurons during baseline conditions when 
salt intake is inhibited. Bottom figure represents glia following changes in the input in response to 




GFAP-ir in the Nucleus of the Solitary Tract 
 Astrocyte abundance in the caudal and middle NTS did not change 2 hours after either 
ISO or FURO treatment, whereas GFAP-ir was decreased 18-24 hours after FURO treatment in 
both the caudal and middle NTS independent of hormone treatment. The NTS contains numerous 
sensory neurons and bundles of fibers that require glial support to connect to other areas in the 
brain. Therefore, the lack of any changes in astrocytes two hours after FURO when the incoming 
signals of hypovolemia are peaking is to be expected. The decrease in astrocytes 18-24 hours 
after FURO may indicate a change in signal transduction requiring less support or a local 
disruption in extracellular homeostasis.   
 
GFAP and Synaptic Protein Expression in the Dorsal Vagal Complex 
 In contrast to the decrease in GFAP-ir found after a single FURO, the protein expression 
of GFAP in the DVC after a single or multiple 18-24 FURO was not appreciably different 
between ISO and FURO treated rats. This may due to using tissue punches encompassing a broad 
area, including the AP, NTS and nuclei in the surrounding areas, where visualizing differences 
are less likely given astrocytes are present in virtually all areas of the brain. Remarkably, the 
change in GFAP expression after a single 18-24 h FURO was greater in EB-treated rats compared 
to that in OIL-treated rats, suggesting a hormonal effect of estradiol on astrocyte abundance in the 
DVC. Looking at the change in GFAP expression after multiple 18-24 h FURO treatments 







 In order to measure physiological and behavioral responses to a body fluid challenge 
repeated multiple times without compounding to volume loss, blood samples were taken from rats 
used for immunohistochemistry and western blot rather than rats used in physiological and 
behavioral studies. Blood was collected at termination for plasma analysis of volume and 
electrolyte status, as repetitive blood sampling may disrupt body fluid balance and instigate a new 
source of stress in the animals. Nonetheless, terminal measures of the plasma revealed increased 
plasma protein and hematocrit after FURO treatment, indicating the loss of fluid volume., 
Hypovolemia was indirectly inferred from the urine volume loss and decreased body weight that 
accompanies FURO-induced hypovolemia as reported previously by us and others (Curtis 2017; 
Rabe 1975). In other words, furosemide was an effective diuretic as demonstrated by the volume 
of urine loss (Fig. 21) and the corresponding body weight loss (Fig. 20) 1- 2 hours after 
furosemide. Furosemide treatment maintained its effectiveness with each treatment, producing 
comparable urine volume losses between subsequent weekly treatments. EB treatment had no 
effect on the diuresis even though EB-treated rats had less urine output than OIL-treated rats after 
the first FURO treatment. EB is known to decrease body weight (Fig. 18) and EB-treated rats 
weighed less than OIL-treated rats (BW before FURO: EB = 296; OIL = 308); therefore it is 
possible that EB-treated rats had less volume to lose.  
 Furosemide was also an effective natriuretic, causing sodium excretion (Fig. 22) 1-2 
hours after furosemide, as determined by measuring the concentration of sodium in the excreted 
urine. Sodium excretion was greatest on week three, most likely due to random variability as 
doses of furosemide were calculated based on body weight and did not differ. Furosemide also 
led to the excretion of potassium (Fig. 23) 1-2 hours after furosemide that was greatest on week 
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three. Urine osmolality (Fig. 24) was not different after FURO. Furosemide blocks reabsorption 
of sodium at the loop of Henley leading to increased sodium in the distal tubule. An increase in 
sodium concentration in the distal tubule reduces water reabsorption, thus both water and sodium 
are excreted. The increase in sodium in the distal tubule of the kidney also increases sodium 
reabsorption in this segment in exchange for potassium, thus potassium is also excreted with 
sodium and can potentially lead to hypokalemia if the natriuresis continues. In general, filtration 
of sodium and potassium were comparable between FURO treatments indicating kidney function 
remain unchanged with each FURO treatment and EB had no effect on renal handling after 
FURO treatment.    
 In order to facilitate hyponatremia, rats were food deprived overnight and only allowed 
access to water. Overnight urinary excretion after FURO did not differ from ISO treated rats and 
was not different between FURO treatment weeks. Overnight excretion of sodium and potassium 
and urine osmolality in FURO treated rats also did not differ from ISO treated rats and was not 
different between FURO treatment weeks. Together, these findings demonstrate that renal 
handling of sodium and potassium was restored to pre-FURO levels during this time. 
Surprisingly, plasma sodium was unchanged after FURO despite the increase in sodium 
excretion, however, the decrease in plasma volume facilitated the maintenance of plasma sodium 
concentrations. Plasma potassium was decreased, mirroring the increase in potassium excretion. 
Plasma osmolarity increased after FURO due to the concentrating effect of hypovolemia and the 
unchanged plasma sodium concentration. Apparent hyponatremia may require additional water 
intake over time to increase the dilution of the extracellular fluid, as demonstrated by Falk in 
1965. Still, rats increased their overnight water intake after FURO compared to the week of ISO 
treatment, validating previous work showing hypovolemia stimulates water intake (Gilman 1937, 
Stricker 1966, Zimmerman 1981).  
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 As an additional determination of the effectiveness of FURO to produce 
hypovolemia/hyponatremia, the fluid status of the rats was determined by calculating sodium and 
water balance after each FURO treatment. FURO treatment resulted in negative sodium balance 
after each treatment, and consistent with urine sodium excretion on week three, there was a 
significantly greater decrement in sodium balance on week three than that on week two and four. 
Rats treated with FURO also were in negative water balance after each treatment and it did not 
differ between treatments. Therefore, FURO produced a significant body fluid challenge by 
depleting water and sodium. 
  
Behavioral Responses 
 In response to water and sodium depletion, rats treated with FURO and then given a 2 
hour 2-bottle intake test increased their water and salt intake compared to rats treated with ISO 
(Figs. 38 and 39). Interestingly, EB-treated rats did not have greater salt intakes than did OIL-
treated rats. The absence of a hormonal effect of salt intake was unexpected. However previous 
studies used intact female rats without accounting for hormone treatment (Sakai 1989). 
Methodological differences may factor into the observed differences as well. The use of different 
methods of sodium depletion (e.g. sodium deficient diet vs. diuretics) and temporal differences in 
protocols result in contradictory findings. Rats permanently housed in metabolic cages with 
testing conducted in home cages compared to rats transferred into metabolic cages for testing may 
behave differently even with an acclimation period (Tarland 2007). 
 Overall, it may be said that furosemide-induced sodium depletion was an effective 
stimulus for producing the physiological responses to water and sodium loss. Rats with and 
without hormone treatment responded to furosemide equally, resulting in negative water and 
sodium balance. Similarly, given there were no differences in excretion of volume or sodium 
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demonstrates the renal compensatory mechanisms to water and salt loss were comparable 
between the groups. Therefore, differences in the central processing of signals related to sodium 
depletion are not due to differences in renal handling.  
 The decrease in the expression of GFAP and the parallel decrease in CaMKII may signify 
a relationship between the two proteins. Glia that do not express GFAP may effectively be 
‘silent,’ inactive, or possibly absent, thereby incapable of performing their role in maintaining the 
synapse and neurotransmission. For instance, if they are unable to provide neurons with calcium, 
the proteins involved in calcium dependent exocytosis of neurotransmitter may be inhibited. In 
effect, excitatory or inhibitory neurotransmission may be blunted. Considering NTS neurons are 
known to provide an inhibitory drive on the central circuit stimulating salt intake, it may be that 
without active glia in the AP and NTS to support neurotransmission, that inhibition is removed, 
thus salt intake ensues. Future studies will consider this avenue with the goal towards 
characterizing the relationship between glia and neurotransmission. 
 In essence, these findings are consistent with our hypotheses and suggest that the 
behavioral plasticity observed in salt intake may be, in part, regulated by brain plasticity 
stimulated by hypovolemia/hyponatremia and involving estradiol influences on astrocytes in the 
dorsal vagal complex. Accordingly, one might predict that preventing the retraction of astrocytes 
from the DVC and thereby preventing passage of any signal of the disturbance into the CNS may 
prevent the stimulation of salt intake. This idea has yet to be tested. However, the indication that 
glial remodeling has functional significance was shown in the supraoptic nucleus of the 
hypothalamus where the release of oxytocin was directly related to a reduction in astrocytic 
coverage of neurons (Chapman 1986; Theodosis 1986). It was later determined that the retraction 
of astrocytes allowed for free diffusion of neurotransmitters to access neurons (Nicholson & 
Sykova 1998). Remarkably, it has also been shown that glial remodeling occurs throughout the 
reproductive cycle (Garcia-Segura et al. 1994) and that estrogen itself can induce changes in 
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astrocytes of the SON (Theodosis and Langle 2006; Theodosis et al. 2006). Identifying estrogen 
receptors on astrocytes in the DVC will further studies where blocking ER’s may demonstrated 
an attenuation in glial remodeling and the detections of peripheral signals due to sodium 
depletion. Again, astrocytes in the AP seem to express a differing morphological and functional 
profile than other astrocytes and thus could play a more active role in neural communication. 
While cells can be positive for GFAP, which identifies them as astrocytes, this doesn’t distinguish 
one astrocyte from another nor does it identify all astrocytes. Investigations into the unique 
properties of astrocytes in the AP will require the development of antibodies to distinguish 
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